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Abstract
While the randomized clinical trial (RCT) is the gold standard for investigating
the effect of a medical intervention, noncompliance to assigned treatments can threaten
a trial’s validity. Noncompliance, if not appropriately controlled, can introduce sub-
stantial bias into the estimate of treatment effect. The complier average causal effect
(CACE) approach provides a useful tool for addressing noncompliance, where CACE
measures the effect of an intervention in the latent subgroup of the study population
that complies with its assigned treatment (the compliers). Meta-analysis of RCTs has
become a widely-used statistical technique to combine and contrast results from multiple
independent studies. However, no existing methods can effectively deal with heteroge-
neous noncompliance in meta-analysis of RCTs. For example, the commonly used meta-
analysis regression methods investigate the impact of study-level variables (e.g., mean
age of the study population) on the study-specific treatment effect size by assuming the
study-level covariates to be fixed. However, noncompliance rates generally differ be-
tween treatment groups within a study and are commonly considered as random rather
than fixed post-randomization variables. In addition, noncompliance may dynamically
interact with the primary outcome and thus affect the response to treatment. Thus,
meta-regression methods are not suitable to controlling for noncompliance.
This thesis focuses on developing Bayesian methods to estimate CACE in meta-
analysis of RCTs with binary or ordinal outcomes. Bayesian hierarchical random effects
models are developed to appropriately account for the inherent heterogeneity in treat-
ment effect and noncompliance between studies and treatment groups. We first present
a Bayesian hierarchical model to estimate the CACE where heterogeneous compliance
rates are available for each study. Second, we extend our approach to deal with incom-
plete noncompliance when some RCTs do not report noncompliance data. The results
are illustrated by a re-analysis of a meta-analysis comparing the effect of epidural anal-
gesia in labor versus no or other analgesia in labor on the outcome cesarean section,
where noncompliance varies substantially between studies. Simulations are performed to
iv
evaluate the performance of the proposed approach and to illustrate the importance of
including appropriate random effects by showing the impact of over- and under-fitting.
Furthermore, we develop an R package, BayesCACE, to provide user-friendly func-
tions to implement CACE analysis for binary outcomes based on the proposed Bayesian
hierarchical models. This package includes flexible functions for analyzing data from a
single RCT and from a meta-analysis of multiple RCTs with either complete or incom-
plete noncompliance data. The package also provides various functions for generating
forest, trace, posterior density, and auto-correlation plots, and to review noncompliance
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1.1 Noncompliance and the causal effect in a single study
Well-conducted randomized controlled trials (RCTs) are considered the hallmark of
evidence-based medicine and the gold standard for evaluating efficacy in clinical re-
search (Holland, 1986). Yet in human randomized experiments, noncompliance with
assigned treatments is common and may induce an information bias in estimating the
average treatment effect (Frangakis and Rubin, 1999). One potential solution to this
problem is intention-to-treat (ITT) analysis. It ignores noncompliance, withdrawal,
and all post-randomization variables, and maintains prognostic balance based on the
original random treatment allocation, but the estimated treatment effect is generally
conservative (Freedman, 1990). Alternative analytic approaches are possible, including
per-protocol analysis, which excludes noncompliant individuals, or as-treated analysis,
which groups individuals by the treatment actually received. However, these approaches
can break randomization and have a high potential for bias in either direction (Little
and Yau, 1998).
Important statistical methods have been developed for analyzing RCT outcomes in
the presence of noncompliance. Two frequently used estimands of treatment efficacy
have been considered, the average treatment effect (ATE) (Little et al., 2009), and
the complier average causal effect (CACE) (Yau and Little, 2001). The ATE is the
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average efficacy across all patients and bounds on ATE have been derived for binary
outcomes (Balke and Pearl, 1997). CACE analysis builds on the principal stratification
framework (Frangakis and Rubin, 2002). The CACE is defined as the average difference
in potential outcomes for the response in a subpopulation of subjects who would comply
with their assigned treatment. The main challenge in CACE modeling is illustrated by
considering treatment outcomes in the four latent classes defined by the intersection
of treatment assignment and treatment compliance: compliers (for whom treatment
received is the same as assigned), never-takers (who do not receive treatment, regardless
of assignment), always-takers (who receive treatment regardless of assignment), and
defiers (who always do the opposite of their treatment assignment).
The core insight of CACE analysis is that it retains the initial randomized assign-
ment, so it overcomes the intrinsic bias associated with per-protocol or as-treated anal-
ysis. Under certain assumptions (see Section 2.1.1 for further discussion), we can derive
an unbiased estimate of the difference in outcomes between compliers in the intervention
group and those in the control group who would have engaged with treatment. Under
some assumptions, CACE has been developed and applied in various settings to account
for noncompliance. For example, Imbens and Rubin (1997) estimated CACE with the
maximum-likelihood (ML) method using the EM algorithm and a Bayesian approach
using the data augmentation algorithm. Little and Yau (1998) incorporated covariates
in this framework via the ML-EM method. Cheng (2009) estimated CACE when the
outcome is ordinal using the ML method. Methods to estimate causal effects under
interference have also been developed recently (Hudgens and Halloran, 2008; Liu and
Hudgens, 2014). However, most of those approaches only consider the setting of a single
randomized clinical trial.
1.2 Causal effects in meta-analysis
To our knowledge, little attention has been paid to estimating causal effects from meta-
analysis of multiple clinical trials accounting for noncompliance. Glasziou (1992) pro-
posed a meta-analysis for“explanatory treatment effect”adjusting for compliance, based
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on the linear model formulation of Newcombe (1988). Later, Baker and Kramer (2005)
proposed ML estimates of “efficacy” when there is switching of interventions (which is
similar to CACE) and briefly discussed its implications for meta-analysis using hypo-
thetical sets of trials. Bannister-Tyrrell et al. (2015) presented fixed-effect meta-analysis
adjusting for compliance in trials using an instrumental variable (IV) estimator. How-
ever, existing meta-regression methods cannot be used directly to derive CACE adjust-
ing for noncompliance for the following reasons: 1) existing meta-regression can only
be used to estimate the impact of fixed study-level covariates on study-specific rela-
tive effect size; 2) noncompliance is observed post-randomization and is considered to
be a random variable; 3) noncompliance rates generally differ between treatment arms
within a study and may affect the response to treatment. We address this gap by ex-
tending the CACE approach for ordinal outcomes from a single clinical trial setting
to meta-analysis settings with multiple clinical trials. Compared to ITT analysis or a
naive meta-regression approach using the averages of post-randomization variables (e.g.,
each study’s average noncompliance rate) as fixed covariates, this method allows us to
appropriately account for the inherent heterogeneity in noncompliance rates between
treatment arms and between studies.
1.3 Noncompliance with missing data in a single study
Besides noncompliance with treatment assignment, missing data also occur frequently in
clinical trials and can affect their validity. Noncompliance occurs when some participants
do not take or receive their assigned treatments, and data can be missing either for
compliance status or for the outcome of interest. Missing outcome or compliance data
happens when study investigators fail to collect those items on some subjects because of
loss to follow-up or other reasons. Ignoring noncompliance or missing data may result
in biased estimates of causal effects in the standard intention-to-treat analysis.
When a study has both noncompliance and missing outcome data, the CACE ap-
proach can still be used but further assumptions about the missing data mechanism are
required. One commonly used assumption is“latent ignorability”(LI), which means that
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the missing data are missing at random conditional on compliance status, i.e., missing-
ness has no residual dependence on the outcomes, given the observed data and the latent
unobserved compliance classes. Under this assumption, several models that accommo-
date missing outcomes have been developed for inference about CACE (O’Malley and
Normand, 2005; Peng et al., 2004). Also, Chen et al. (2009) discussed identifiability and
estimation of CACE with missing outcome data under a nonignorabilility assumption,
i.e., when the missing data mechanism depends on the unobserved outcome. Analytical
strategies for handling noncompliance are also increasingly used (Jo et al., 2010; Stuart
et al., 2008), although not as widely as missing data methods.
1.4 Handling missing data and noncompliance in meta-
analysis
Although inference for a clinical trial with noncompliance or missing data has been well
studied, little attention has been paid to handling both missing data and noncompliance
in meta-analysis. Meta-analysis, the statistical approach for synthesizing evidence from
multiple sources, is gaining popularity in many fields due to the rapid growth of interest
in comparative effectiveness research and evidence-based medicine (Egger et al., 2008).
While multivariate and network meta-analysis (NMA) methods have been developed
recently for meta-analyses of data consisting of multiple outcomes, multiple treatments,
or multiple diagnostic tests (Lumley, 2002; Jackson et al., 2011; Zhang et al., 2014;
Riley et al., 2017; Ma et al., 2018; Lian et al., 2018), important research gaps remain
in meta-analysis in the area of causal inference. In particular, researchers have only re-
cently started investigating causal effects in meta-analysis accounting for noncompliance
(Baker and Kramer, 2005).
When noncompliance data are reported in each trial, intuitively one can first estimate
CACE for each study, then combine these estimates using a meta-analytic method such
as a fixed- or random-effect model to estimate the population-averaged CACE. We call
this naive method a “two-step” approach. For ordinal or binary outcomes, we first
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propose in Chapter 2 a Bayesian hierarchical model for estimating CACE in meta-
analysis to account for noncompliance that is heterogeneous between studies, but this
method is feasible only when the randomized allocation, actual taken treatment, and
outcomes per treatment and allocation group of each study are recorded. However,
existing meta-analysis methods cannot handle both noncompliance and missing data
simultaneously. The two-step approach — which can be viewed as a special case of a
model using only trials with complete noncompliance data — can thus be less efficient
and potentially biased because trials without noncompliance data are excluded.
1.5 R packages to perform CACE analysis
An important step in promoting new statistical methods is to provide open-source user-
friendly software. Several R packages are available to perform CACE analysis in a single
study. For example, the noncomplyR package (Coggeshall, 2017) provides convenient
functions for using Bayesian methods to perform inference on the CACE. The package
eefAnalytics (Kasim et al., 2017) provides tools for exploratory CACE analysis of simple
randomized trials, cluster randomized trials, and multi-site trials with focus on education
trials. Besides the CACE analysis, another method quite commonly used to account
for noncompliance is the instrumental variable (IV) method estimating the treatment
effect with two-stage least squares (2SLS) regression (White, 1982); the R package ivpack
(Jiang and Small, 2014) performs this type of analysis.
However, for analyzing multiple trials in the presence of noncompliance, little soft-
ware is available for causal effect analysis and specifically for meta-analysis. When
noncompliance data are reported in each trial, intuitively one could implement a two-
step approach by first estimating CACE for each study and then combining the study-
specific estimates using a fixed-effect or random effects model to estimate the population-
averaged CACE. In Chapter 2 we propose a Bayesian hierarchical model to estimate
the CACE in a meta-analysis of randomized trials where compliance may be heteroge-
neous between studies. This chapter is published in Biometrics (Zhou et al. (2019)).
In addition, it is also common that noncompliance data is not available for some trials.
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Simply excluding trials with incomplete noncompliance data from a meta-analysis can
be inefficient and potentially biased. In Chapter 3 we propose an improved flexible
Bayesian hierarchical CACE framework to account simultaneously for heterogeneous
noncompliance and incomplete noncompliance data. The package BayesCACE focuses
on providing user-friendly functions to estimate CACE in either a single study or meta-
analysis using models based on Zhou et al. (2019) and on Chapter 3.
6
Chapter 2





As introduced in Section 1.2, existing meta-regression methods cannot be used directly
to estimate causal effects adjusting for noncompliance. We address this gap by ex-
tending the CACE approach for ordinal outcomes from a single clinical trial setting to
meta-analysis settings with multiple clinical trials. Compared with ITT analysis or a
naive meta-regression approach using the averages of post-randomization variables (e.g.,
each study’s average noncompliance rate) as fixed covariates, this method allows us to
appropriately account for the inherent heterogeneity in noncompliance rates between
treatment arms and between studies.
This chapter is organized as follows. Section 2.1 presents our Bayesian hierarchical
modeling approach and explains the model assumptions. Section 2.2 gives a case study
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reanalyzing a meta-analysis comparing epidural analgesia versus no or other analgesia in
labor on the outcome of cesarean section, where noncompliance varies between studies.
Section 2.3 presents a comprehensive simulation study evaluating the performance of
our approach under a variety of conditions. Finally, Section 2.4 discusses our findings
and implications for future developments.
2.1 Statistical Methods
2.1.1 Notation and assumptions
We consider I two-armed randomized trials. For the ith trial, let Ni be the number of
subjects, where Ni0 are randomly assigned to the control group and Ni1 are assigned to
active treatment. Let Ri be the Ni-dimensional vector of randomization assignments
for all subjects, with individual element Rij = r corresponding to whether subject j is
assigned to treatment (r = 1) or control (r = 0). Let T ri be the Ni-dimensional vector
of potential treatments received under the randomization assignments r with individual
element T rij , where T
r
ij = t ∈ {0, 1} according to whether subject j actually took the
active treatment (t = 1) or placebo (t = 0) under r. Let Y r,ti be the vector of potential
outcomes under randomization assignment r and treatment received t, with individual
element Y r,tij for the j
th subject in the ith trial. In this study, we consider only ordinal
outcomes Y r,tij = o ∈ {1, . . . , O}. Note that the sets of {Y
r,t
ij } and {T rij} are potential
outcomes and treatment-received status, where for each (i, j), only one of the possible
values of each set can be observed, so we denote the observed response and received
treatment as Yij and Tij for the j
th subject in the ith trial.
Following Imbens and Rubin (1997), we let Cij be the latent compliance class of the
jth patient in the ith trial, defined as follows:
Cij =

0, never-taker, if (T 0ij , T
1
ij) = (0, 0)
1, complier, if (T 0ij , T
1
ij) = (0, 1)
2, always-taker, if (T 0ij , T
1
ij) = (1, 1)
3, defier, if (T 0ij , T
1
ij) = (1, 0).
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In a two-arm trial, we can only observe one of T 1ij and T
0
ij so a subject’s compliance
status Cij is not an observable variable. It can only be partially identified based on
treatment assignment and observed treatment received (see Table 2.1 columns Rij , Tij ,
and Cij).
Table 2.1: Observed groups, latent compliance classes and outcome probabilities of trial
i
Rij Tij Cij Yij = o ∈ {1, . . . , O} Count
0 0 0 (never-taker) or 1 (complier) M(ni00, qio =
πicvio+πinsio
1−πia ni00o
0 1 2 (always-taker) or 3 (defier) M(ni01, bio) ni01o
1 0 0 (never-taker) or 3 (defier) M(ni10, sio) ni10o
1 1 1 (complier) or 2 (always-taker) M(ni11, pio =
πicuio+πiabio
1−πin ni11o
Defiers are ruled out by the monotonicity assumption.
To identify treatment effects of interest, for each study we make assumptions iden-
tical to those listed in Angrist et al. (1996) and describe their implications below.
Assumption 1: Stable unit treatment value assumption (SUTVA) (Rubin, 1980).
The outcome for a subject is unaffected by the particular assignments of treatments to
the other individuals. That is, if r = r′ then T rij = T
r′
ij ; and if r = r
′ and t = t′ then
Y r,tij = Y
r′,t′
ij .
Assumption 2: Random assignment to randomization groups. For all Ni subjects in
the ith trial, the treatment assignment Ri is random. This assumption implies that the
proportion of each compliance class should be the same in the intervention and control
groups.
Assumption 3: Exclusion restriction. For subject j in the ith trial, Y r,tij = Y
r′,t
ij for
all r, r′ and t, i.e., the randomization assignment affects responses only through its
effect on treatment received. With this assumption, Assumption 1 can be restated: if
t = t′ then Y r,tij = Y
r′,t′
ij for any r, r
′. Therefore, for always-takers and never-takers,
the distribution of outcomes does not depend on randomization group.




T 0ij ] 6= 0. The fraction of subjects who receive each intervention varies by randomization
group.
Assumption 5: Monotonicity. P [T 1ij ≥ T 0ij ] = 1 for each trial. This means that
no subject necessarily receives the treatment opposite to the randomized assignment,
under assignment to either active treatment and control. This assumption rules out the
existence of defiers, so it reduces the number of compliance types and permits a properly
identified model (see Table 2.1).
2.1.2 Estimation and inference for the causal effect
For discrete outcomes, we extend the notation in Cheng (2009) and Baker (2011), and
define the following parameters under the latent compliance model: 1) πia, the prob-
ability of being an always-taker in the ith study; 2) πin, the probability of being a
never-taker in the ith study, so the probability of being a complier in the ith study, πic,
is 1 − πia − πin; 3) uio, the probability a complier randomized to the treatment group
has outcome o in the ith study; 4) vio, the probability a complier randomized to the
control group has outcome o in the ith study; 5) sio, the probability a never-taker has
outcome o in the ith study; and 6) bio, the probability an always-taker has outcome o








o=1 bio = 1. The study-
specific probabilities πia, πin, uio, vio, sio, and bio may be assumed to be draws of their
respective random effects, which follow some common distributions, discussed below.
Table 2.1 shows the distributions of observed nirt in terms of the parameters for
trial i, where nirt =
∑
j I(Rij = r, Tij = t) denotes the number of individuals in each
observed group and M(nirt,xio) denotes a multinomial distribution with nirt subjects
and multinomial probabilities {xio}. The observed count for each outcome o in group
{j : Rij = r, Tij = t} is nirto, o = 1, . . . , O. Although latent compliance classes cannot
be fully identified based on randomization group (Rij) and observed treatment-received
behaviors (Tij), the randomization assignment and the exclusion restriction assumptions
imply that 1) the proportions of always-takers, never-takers and compliers in the control
group are equal to those in the treatment group; 2) for never-takers and always-takers,
the outcome distribution under control is the same as that under active treatment. They
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further give qio =
πicvio+πinsio
1−πia and pio =
πicuio+πiabio
1−πin as probabilities corresponding to
ni00o and ni11o, o ∈ {1, . . . , O} (shown in Table 2.1).
One causal effect of interest in many studies is the CACE discussed in Section 1.1.
For an ordinal outcome Yij = o ∈ {1, . . . , O}, suppose we can code scores {W1,W2, . . . ,WO}










(Wo × vio). (2.1)
The overall causal effect from the meta-analysis of I trials θCACE can be defined
as θCACE = E(θ
CACE
i ). It is often unclear how to select scores {W1,W2, . . . ,WO} to
reflect distances between categories. Equally spaced scores {1, 2, ..., O} or their linear
transforms are sensible in many cases and provide a reasonable compromise when there
is no obvious choice (Agresti, 2003). Alternative scoring systems such as midranks are
also possible. When uncertain about which scoring choice to use, a sensitivity analysis
can consider different sensible choices to see how they affect the results.
2.1.3 Likelihood and the Bayesian hierarchical model
For the ith trial, let λi denote the probability P (Rij = 1), which is usually known
and can therefore be treated as fixed. Let βi = (πia, πin, si, bi,ui,vi), where si =
(si1, . . . , si(O−1)), bi = (bi1, . . . , bi(O−1)), ui = (ui1, . . . , ui(O−1)), vi = (vi1, . . . , vi(O−1)),






{(1− λi)(πicvio + πinsio)}(1−Rij)(1−T ij)I(Yij=o){(1− λi)πiabio}(1−Rij)TijI(Yij=o)
{λiπinsio}Rij(1−T ij)I(Yij=o){λi(πicuio + πiabio)}RijTijI(Yij=o), (2.2)
where j = 1, . . . , Ni, o = 1, . . . , O, πic = 1 − πia − πin, the indicator function I(Yij =








o vio = 1, and
0 ≤ πia, πin, πic, sio, bio, uio, vio ≤ 1.
The likelihood for all trials in a meta-analysis is L(β) =
∏
i Li(βi). Using the mul-
tivariate random effects meta-analysis framework (Jackson et al., 2011), one can specify
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βi ∼ F (β0,Σ0) where F is some distribution function, β0 is the overall mean param-
eter and Σ0 is the variance-covariance matrix. In a Bayesian framework, one would
also specify the prior distributions of β0 and Σ0 as f(β0) and f(Σ0), respectively. The
joint posterior distribution is then proportional to
∏
i Li(βi)F (βi|β0,Σ0)f(β0)f(Σ0).
The posterior distribution can be estimated by Markov chain Monte Carlo (MCMC)
methods, specifically the Gibbs and Metropolis-Hastings sampling algorithms (Gelfand
and Smith, 1990).
2.1.4 Accounting for heterogeneity through random effects models
Between-study heterogeneity commonly exists in a meta-analysis because studies usually
differ in their subject recruitment methods, measurement techniques, study qualities,
etc.. To account for potential between-study heterogeneity of the fractions in the com-
pliance classes and of the outcome probabilities, we consider a random-effects model.
To guarantee the desired properties of the probabilities of being in each principal
stratum in study i, i.e., πin + πia + πic = 1, and 0 ≤ πin, πia, πic ≤ 1, and to allow






, where ni = αn+ δin, ai = αa+ δia, and (δin, δia)
T ∼ N(0, Σps). To al-





To be consistent with the case study presented in Section 2.2, we describe the rest
of the model for the binary case, where o ∈ {0, 1}, i.e., si0 + si1 = bi0 + bi1 = ui0 +
ui1 = vi0 + vi1 = 1 for the i
th trial, so the vector parameters of si, bi,ui,vi become
scalars si1, bi1, ui1, vi1. Specifically, we assume a normal distribution for each response
probability si1, bi1, ui1, and vi1 on the transformed scales, and allow heterogeneity
between studies: g(si1) = αs + δis, g(bi1) = αb + δib, g(ui1) = αu + δiu, g(vi1) = αv + δiv,
where g(·) is a link function such as the logit or probit. We then assume the probabilities
of having an outcome are independent across principal strata, so δis ∼ N(0, σ2s), δib ∼
N(0, σ2b ), δiu ∼ N(0, σ2u), δiv ∼ N(0, σ2v). To extend this model to more general cases
with outcomes taking more than two values, one could fit a generalized logit model, e.g.,
the baseline-category logit model for nominal responses or the cumulative logit model
for ordinal responses (Agresti, 2003).
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2.1.5 Implementation
We used a Bayesian hierarchical model (Gelman et al., 2013), fit using JAGS. To avoid
over-fitting the data with an excess of random effects, we used a forward selection pro-
cedure on the random effects. Specifically, at each forward step, we added the random-
effect component that provided the largest improvement in the deviance information
criterion (DIC) (Spiegelhalter et al., 2002). Other model-selection approaches are easily
substituted for these choices, e.g., using a different model-selection criterion (Celeux
et al., 2006), or a different search strategy.
Computation used Markov chain Monte Carlo (MCMC) in JAGS, interfacing with
R using the package “rjags”. Each fit consisted of three independent chains initiated
with parameter values drawn randomly from their prior distributions. Each chain was
allowed 10,000 iterations of burn-in, and the subsequent 100,000 iterations were col-
lected as posterior samples. Estimates are presented as the posterior mean with a
95% credibility interval. Convergence of Markov chains was assessed using trace plots,
sample autocorrelation, and the Gelman and Rubin convergence statistic (Gelman and
Rubin, 1992). We also used the R package “mcmcse” (Flegal et al., 2017) to calculate
the effective sample size and to make sure the chains gave adequately precise posterior
estimates.
2.2 Case Study
2.2.1 Data and descriptive analysis
We reanalyzed the data from a meta-analysis of the impact of epidural analgesia in labor
compared with no or other analgesia, on the outcome of cesarean section (Bannister-
Tyrrell et al., 2015). Epidural analgesia in labor is a highly effective method of labor pain
relief, but there is a controversy over whether epidural analgesia in labor is associated
with an increased risk of cesarean delivery. However, noncompliance is common in
RCTs in obstetrics: it is unethical to deny laboring women their preferred mode of
labor analgesia because trial entry and randomization occurs before the experience of
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labor pain. Thus the ITT result is not a good estimate of the consequence of receiving
epidural analgesia due to noncompliance, and it motivates us to investigate the causal
effect. Data were recorded on randomized treatment assignment (1=Epidural analgesia,
0=No/other analgesia in labor), treatment actually received (1=Epidural analgesia,
0=No/other analgesia in labor), and frequency of cesarean section (1=Yes, 0=No) by
compliance with allocated intervention. 10 RCTs had complete data available on the
number of cesarean sections in compliant and noncompliant participants, which could
be meta-analyzed.
In these 10 trials, 1,684 women were randomly assigned to epidural analgesia, with
130 cesarean deliveries, and 1,732 were assigned to no/other analgesia with 115 cesarean
deliveries. Unlike the ITT and IV analysis used by Bannister-Tyrrell et al. (2015), in
which the data from Nikkola et al. (1997) were excluded because it had no cesarean
section events, we included this trial because our Bayesian method accommodates trials
with zero events.
Figure 2.1 displays the noncompliance rates of these studies, where P(T = 1|R = 0)
is the fraction of participants who were randomized to no/other analgesia in labor but
actually received epidural analgesia, and P(T = 0|R = 1) is the fraction of partic-
ipants who did not receive epidural analgesia among those who were assigned to it.
Because several arms had 0 events, the confidence intervals were calculated using an
exact method, the Clopper-Pearson exact interval (Clopper and Pearson, 1934). We
adopted a bivariate generalized linear mixed effects model (BGLMM) (Chu and Cole,
2006) to model the two overall noncompliance rates. The BGLMM assumes a bivariate
normal distribution for the logits of the probabilities in the two groups: logit(p1i) =
µ1 + η1i, logit(p0i) = µ0 + η0i, (η1i, η0i)
T ∼MVN(0,Ση), where p0i = P(T = 1|R = 0)
and p1i = P(T = 0|R = 1). As shown in Figure 2.1, the noncompliance rates varied
substantially across studies. The index of heterogeneity I2 (Higgins and Thompson,
2002) was 98.48% for P(T = 1|R = 0) and 98.07% for P(T = 0|R = 1). The high
heterogeneity motivated us to apply Bayesian hierarchical models to estimate CACE
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Figure 2.1: Forest plot of study-specific noncompliance rates in studies of epidural
analgesia. The center of each square/circle and the horizontal lines represent the corre-
sponding probability with 95% exact confidence interval. The diamonds indicate overall
estimates of noncompliance rates using the bivariate generalized linear mixed effects
model (BGLMM). This figure appears in color in the electronic version of this chapter.
In this case study, the SUTVA assumption holds because a participant’s outcome
did not depend on the other participants’ treatments. The exclusion restriction as-
sumption holds because a participant’s randomized assignment affected the cesarean
section outcome only through the analgesia that was actually received. The other three
assumptions are also reasonable based on the randomized clinical trial design.
2.2.2 Likelihood and priors
As discussed in Section 2.1.4, for a binary outcome (o ∈ {0, 1}) the parameter vector
is reduced to βi = (πia, πin, si1, bi1, ui1, vi1). From Table 2.1, the probability of each
observed nirto is determined by the above parameters. Therefore, the i
th trial’s contri-
bution to the likelihood is
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Li(βi) = [(1− λi){πic(1− vi1) + πin(1− si1)}]
ni000{(1− λi)(πicvi1 + πinsi1)}ni001
{(1− λi)πia(1− bi1)}ni010{(1− λi)πiabi1}ni011{λiπin(1− si1)}ni100
{λiπinsi1}ni101 [λi{(πic(1− ui1) + πia(1− bi1)}]ni110{λi(πicui1 + πiabi1)}ni111 (2.3)
and the likelihood for all trials in the meta-analysis is L(β) =
∏
i Li(βi).
Using equally spaced scores (W0 = 0,W1 = 1), the CACE for study i is θ
CACE
i =
ui1 − vi1, the response rate difference in compliers. Using the model introduced in
Section 2.1.4, the medians of ui1 and vi1 can be estimated as M(ui1) = g
−1(αu) and
M(vi1) = g




































E(θCACEi ) involves an integral, the probit-link random effects model implies closed-
form formulas E(ui1) = Φ(
αu√
1+σ2u
) and E(vi1) = Φ(
αv√
1+σ2v
), and the logit-link random
effects model has a well-established approximation, E(ui1) ≈ logit−1( αu√
1+C2σ2u
) and
E(vi1) ≈ logit−1( αv√
1+C2σ2v
), where C = 16
√
3
15π (Zeger et al., 1988).
We selected proper but diffuse prior distributions for the hyper-parameters because
non-informative prior distributions can lead to inaccurate posterior estimates (Natara-
jan and McCulloch, 1998). For fixed effects, vague priors were assigned. In particular,
αn and αa both follow N(0, 2.5
2), so under the simplest situation (a fixed effects model),
a 95% prior probability interval for any of the probabilities πin, πia, πic would range from
about 0.001 to 0.91; and αs, αb, αu, αv all follow N(0, 2
2), which implies a 95% interval
for the probabilities si1, bi1, ui1, vi1 ranging from about 0.01 to 0.98. The hyper-priors






v were assumed to be Gamma(2, 2), which
implies a 95% interval (0.36, 8.36) for the variance parameters, allowing moderate het-
erogeneity for the response probabilities. The prior for the precision matrix Σ−1ps was
Wishart, i.e., W (I, 3), where I is the identity matrix. In the reduced model with one
of σ2n, σ
2
a set to 0, the prior of the other precision parameter was still assumed to be
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Gamma(2, 2), which gave moderate heterogeneity for latent principal strata probabili-
ties.
2.2.3 Model selection and results
We adopted the forward selection procedure introduced in Section 2.1.5 to search for the
best-fitting model. The models specified in Section 2.1.4 have 6 potential random effects
in total: δin, δia, δis, δib, δiu and δiv. In each step of the forward-selection procedure,
we added the random-effect component that provided the largest improvement in DIC.
Table 2.2 presents DIC, DIC improvement, and the effective number of parameters (pD)
for each model fit to the 10 studies. Starting with the simplest model with no random
effects (Model I), the largest improvement was obtained by allowing the probability of
being an always-taker to be a random effect, i.e., adding δia (Model IIf). In the second
step, adding a random effect for the probability of being a never-taker δin (Model IIIe)
decreased DIC the most. This revealed an important characteristic of this meta-analysis:
the studies might vary considerably in their recruitment criteria, study procedures,
beliefs of the local PIs, etc., resulting in different properties of the latent compliance
classes. The next forward step produced a meaningful improvement by including a
random effect for the cesarean section rate of a never-taker, δis (Model IVa). The
resulting improvement was modest compared to adding random effects δia and δin. It is
difficult to say what constitutes an important difference in DIC; we follow Lunn et al.
(2012) in considering that a reduction of less than 5 is not a substantial improvement.
In the last step, DIC was reduced only by 3.6 compared to Model IVa, so the final model
included random effects δia, δin, and δis.
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Table 2.2: Selection of random effects using a forward selection
procedure on RCTs of epidural analgesia in labor
Random effects models DIC DIC improvement pD
Model I (None) 917.4 N/A 6.0
Model IIa (δis) 896.8 20.6 21.3
Model IIb (δib) 918.3 -0.9 16.1
Model IIc (δiu) 915.0 2.4 12.4
Model IId (δiv) 907.4 10.0 14.1
Model IIe (δin) 577.1 340.3 13.6
Model IIf (δia) 537.2 380.2 15.7
Model IIIa (δia, δis) 514.9 22.3 29.3
Model IIIb (δia, δib) 538.6 -1.4 19.5
Model IIIc (δia, δiu) 531.9 5.3 21.1
Model IIId (δia, δiv) 526.3 10.9 22.9
Model IIIe (δia, δin) 265.7 271.5 21.4
Model IVa (δia, δin, δis) 246.5 25.0 27.3
Model IVb (δia, δin, δib) 266.5 5.0 24.9
Model IVc (δia, δin, δiu) 262.1 9.4 28.2
Model IVd (δia, δin, δiv) 267.1 4.4 29.3
Model IVe (δia, δin, ρ) 265.7 5.8 22.1
Model Va (δia, δin, δis, ρ) 246.2 0.3 27.6
Model Vb (δia, δin, δis, δib) 247.2 -0.7 30.7
Model Vc (δia, δin, δis, δiu) 242.9 3.6 34.0
Model Vd (δia, δin, δis, δiv) 253.0 -6.5 34.4
Bold-face cells are models selected using the forward selection pro-
cedure. DIC improvement is the reduction in DIC compared to
the previous step’s lowest DIC. The study-specific component cor-
responding to each random effect: δis never-taker response, δib
always-taker response, δiu treated complier response, δiv control
complier response, δin never-taker probability, δia always-taker
probability; ρ is the correlation between δia and δin.
18
Figure 2.2 is a forest plot of θCACEi for each study individually, using the Bayesian
method with the foregoing priors. The first overall estimate of θCACE is from the final
model (Model IVa). The second estimate is the REML (restricted maximum likelihood)
estimate calculated using the individual posterior means and standard errors of the
θCACEi . We call this method the “two-step” approach because it first analyzes each
study separately, then combines the individual estimates to give a pooled eastimate of
θCACE. The estimated θCACEi varied from negative to positive in individual studies,
but the 95% credible intervals all cover zero. Among overall estimates, the two-step
approach gave a wider interval than our proposed method, suggesting it may not be
efficient because it required the whole set of parameters to be estimated for each study,
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Figure 2.2: Forest plot of CACE of epidural analgesia in labor on caesarean section.
The center of each square and the horizontal lines represent the posterior medians and
95% equal tail credible intervals of θCACEi for each individual study based on separate
analyses. A diamond indicates the pooled estimate of θCACE and its 95% credible
interval or confidence interval. The first overall estimate comes from the selected final
model, Model IVa; the second one is from the REML estimator under a random-effect
model using the two-step approach; the third one is the overall risk difference (RD) from
the fixed-effect ITT analysis. This figure appears in color in the electronic version of
this chapter.
The ITT fixed-effect meta-analysis gave an estimated risk difference of 0.011 with
95% confidence interval (-0.005, 0.027); the overall θCACE from our final model, 0.022
(−0.003, 0.048), was not significant either, though the point estimate was about twice of
that from the ITT analysis in the same direction. Thus we conclude that the potential
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dilution of the ITT estimated treatment effect notwithstanding, epidural analgesia in
labor does not affect the risk of cesarean section in the view of causal interpretation.
2.3 Simulation Studies
To evaluate the performance of our modeling approach and to study the impact of mis-
specification of random effects, we performed four sets of simulations. For ease of presen-
tation and interpretation, we generated data with, at most, random effects only for the
latent compliance class probabilities and the response probabilities of treated compliers,
(δin, δiu), then fit models with up to three random effects (δin, δiu, δiv). Specifically,
data were simulated from the following four models: 1) no random effects; 2) random
effect for latent compliance class probabilities δin; 3) random effect for the response
probabilities of compliers in the treatment group δiu; and 4) random effects for both δin
and δiu. The simulations are realistic scenarios that researchers are likely to encounter,
such as those in the case studies.
We simulated 2000 meta-analysis datasets in each setting. For each dataset, 20
studies were simulated, each with 350 observations, roughly matching the sample sizes
in our case study. In each simulated study, the allocation ratio was 1:1 (λi = 0.5). True
values were set to (αn, αa, αs, αb, αu, αv) = (−0.4,−0.6, 0.5,−0.5,−0.5, 0.5), giving true
values πin = 0.302, πia = 0.247 and θ
CACE
i = −0.383 in the absence of random effects.
In the presence of random effects, the variances of δin, δiu were set to 0.5
2 so the true
θCACE was approximately −0.364 when δiu was present.
For each simulated dataset, we fit models with: 1) no random effects; 2) one random
effect, for δin, δiu, or δiv; 3) two random effects, for [δin, δiu], [δin, δiv], or [δiu, δiv]; and 4)
three random effects, for [δin, δiu, δiv]. Each analysis used JAGS with forward selection
using DIC. Table 2.3 summarizes the estimated probability of selecting each candidate
model as the “best” model in each simulation setting. DIC identified the true random
effects model with probability over 0.95, i.e., our procedure usually selected the correct
random effects and thus usually accounted properly for uncertainty in the estimates.
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Table 2.3: Estimated probability of selecting each candidate model using DIC*, based on
2000 simulated datasets
True Random Selected Random Effects Model
Effects Model None δin δiu δiv δin, δiu δin, δiv δiu, δiv δin, δiu, δiv
None 95.05 1.60 1.85 1.45 0 0.05 0 0
δin 0 96.25 0 0 1.85 1.90 0 0
δiu 0 0 96.65 0 1.25 0 2.00 0.10
δin, δiu 0 0 0 0 98.25 0 0 1.75
Bold-face cells give the estimated probability of identifying the correct model. The numbers
have been multiplied by 100 for presentation.
*DIC: deviance information criterion.
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Table 2.4: Performance of estimates and credible intervals for θCACE for each model, based on 2000
simulated datasets
True Random Selected Random Effects Model
Effects Model None δin δiu δiv δin, δiu δin, δiv δiu, δiv δin, δiu, δiv
None
Mean -0.383 -0.383 -0.373 -0.374 -0.372 -0.374 -0.363 -0.363
Bias 0.000 0.000 0.010 0.009 0.011 0.009 0.020 0.020
95% CIL* 0.100 0.099 0.171 0.171 0.170 0.172 0.220 0.221
95% CICp** 0.947 0.948 0.999 0.999 0.999 0.999 1.000 1.000
δin
Mean -0.383 -0.382 -0.372 -0.374 -0.372 -0.373 -0.364 -0.363
Bias 0.000 0.001 0.011 0.009 0.011 0.010 0.019 0.020
95% CIL 0.101 0.098 0.172 0.173 0.170 0.175 0.222 0.223
95% CICp 0.946 0.947 0.998 0.999 0.998 0.999 1.000 1.000
δiu
Mean -0.365 -0.364 -0.356 -0.355 -0.355 -0.355 -0.346 -0.346
Bias -0.001 0.000 0.008 0.009 0.009 0.009 0.018 0.018
95% CIL 0.100 0.099 0.204 0.171 0.204 0.172 0.247 0.248
95% CICp 0.755 0.759 0.986 0.944 0.986 0.946 0.995 0.996
δin, δiu
Mean -0.365 -0.365 -0.357 -0.356 -0.356 -0.355 -0.348 -0.347
Bias -0.001 -0.001 0.008 0.008 0.008 0.009 0.016 0.017
95% CIL 0.101 0.099 0.205 0.173 0.204 0.175 0.249 0.250
95% CICp 0.763 0.753 0.986 0.951 0.987 0.951 0.997 0.996
Bold-face cells are the correct model.
*95% CIL: 95% equal-tail credible interval length.
**95% CICp: 95% credible interval coverage probability.
Table 2.4 shows the estimated mean, bias, 95% credible interval length, and coverage
probability for θCACE under each model. We present results only for θCACE because of
space limitations. In general, the posterior standard deviation becomes larger as more
random effects are included. Over-fitting (including a random effect when it is absent)
tends to give longer 95% credible intervals. As for the coverage probabilities, 1) under
the correct model or when over-fitting occurs, the coverage probabilities are close to or
greater than the nominal 0.95; and 2) when under-fitting occurs (omitting a random
effect when it is present), failure to include the random effect for the study-specific
probability of latent compliance groups (δin) does not substantially affect the coverage
probability, but failure to include the random effect for the response rate of a treated
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complier (δiu) reduces coverage for θ
CACE notably.
2.4 Discussion
To estimate complier average causal effects in meta-analysis of RCTs with noncom-
pliance, we proposed a Bayesian hierarchical model that accounts for between-study
heterogeneity and applied it to a meta-analysis of epidural analgesia trials. We also
performed simulation studies to evaluate the performance of our approach and the im-
pact of misspecification of random effects. To the best of our knowledge, this is the first
meta-analysis of RCTs estimating CACE accounting for noncompliance.
In the case study we compared the estimate of θCACE from the “two-step approach”
with the one from our proposed final model. The two-step approach can be a valid
alternative to our proposed random-effect model. However, this approach requires the
whole set of parameters to be estimated independently for each study. Thus, the total
number of effective parameters may be larger, making it potentially not as efficient as the
one-step approach. Also, after computing θCACEi and SE(θ
CACE
i ) from posterior samples
(which depends on large-sample theory), various methods could be used to account for
the heterogeneity besides the REML estimator we used, e.g., the DerSimonian-Laird,
Hedges, or Hunter-Schmidt estimators (Viechtbauer, 2005), which may complicate the
estimation.
The control procedure in this case study is defined as “nonepidural or no analge-
sia in labor”, so the control treatment varies between studies, making it possible that
the corresponding population of each latent class is not identical across studies. Be-
cause θCACEi in Figure 2.2 was estimated from separate analysis only using data from
study i, the study-specific θCACEi could be interpreted slightly different depending on
what the particular control procedure for that study was. However, the different sub-
populations of compliers in individual studies are considered subsets of the general
“compliers” population defined for the meta-analysis comparing epidural analgesia in
labor with nonepidural or no analgesia. The estimand θCACE is thus still sufficiently
well-defined and its interpretation is not affected.
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Note that the CACE is defined under the principal stratification framework assuming
SUTVA, random assignment, the exclusion restriction, E[T 1ij−T 0ij ] 6= 0, and monotonic-
ity. In our case study, the assumptions are plausible as discussed in Section 2.2.1. In
other cases, some assumptions may be violated; accounting for these violations will in-
crease the complexity of defining and estimating causal effects. Moreover, the CACE
analysis typically assumes that compliance status is reported without error, but this
might be invalid for self-reported compliance. Therefore, further research is needed on
the consequences of relaxing key assumptions and incorporating noncompliance mea-
surement errors. Some extensions have been developed for a single randomized trial,
e.g., estimating causal effects in the presence of interference (Liu and Hudgens, 2014),
noncompliance measured with error (Imai and Yamamoto, 2010), and incorporating
baseline covariates (Roy et al., 2007). Extensions to meta-analysis of RCTs incorporat-
ing those issues await further development.
Also, as a reviewer noted, in our epidural analgesia case study, compliance may be
strongly determined by external factors such as the severity of pain. Pain severity is
another post-randomization variable that is determined after randomization and may
relate to both the actual taken treatment and the outcome. Randomization should have
made the pain severity balanced between treatment arms. However, pain may influence
the behavior of compliance differently in the treatment and control arms: in the epidural
analgesia group, severe labor pain may reduce the rate of noncompliance, while in the
control group, severe labor pain possibly increases the rate of noncompliance. Other
possible post-randomization variables could include the length of labor. However, it
is hard to measure pain severity and for our example meta-analysis, we do not have
data on that or other post-randomization variables. Methods for handling such post-
randomization variables deserve further investigation.
2.5 Supporting Information
Data analyzed in Section 2.2, parameter estimates from the fixed effects model (Model
I) and the final model (Model IVa), sample R JAGS code implementing Model IVa
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for the case study, sensitivity analysis on prior distributions, and additional simulation
scenarios are available in the Appendix at the end of the thesis.
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Chapter 3
A Bayesian Hierarchical CACE
Model Accounting for Incomplete
Noncompliance Data in
Meta-analysis
The present chapter’s main purpose is to develop a flexible statistical framework to use
noncompliance data that is both heterogeneous and incomplete across studies, in a meta-
analysis of RCTs with ordinal or binary outcomes. The idea is motivated by a meta-
analysis, conducted by Bannister-Tyrrell et al. (2015), of the effect of epidural analgesia
in labor on the occurrence of cesarean section, in which only 9 of 27 studies were included
because only 10 studies had full compliance data and 1 other study was excluded because
it had zero cesarean section events. Our proposed Bayesian hierarchical framework can
include studies that do not report noncompliance data and studies with zero events.
This rest of this chapter is organized as follows. Section 3.1 describes the moti-
vating case study of epidural analgesia, in which noncompliance varies between studies
and compliance status was missing for 17 of 27 studies. Section 3.2 first presents the
assumptions for estimating the causal effect and for missingness, then describes our
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Bayesian hierarchical modeling approach and describes how we obtained posterior dis-
tributions for the overall and study-specific CACEs. Section 3.3 applies the model to
the epidural analgesia case study using a particular approach to model selection and
conducts sensitivity analysis to the missing data assumptions. Section 3.4 presents sim-
ulation studies evaluating the performance of our approach under a variety of conditions.
Finally, Section 3.5 discusses our findings and potential extensions in future work.
3.1 A Motivating Study
3.1.1 Data Sources
Epidural analgesia in labor is a highly effective method of labor pain relief, but it
remains controversial whether epidural analgesia in labor increases the risk of cesarean
section delivery. Nonetheless, good evidence to support or refute this association is
still limited, mainly because randomized controlled trials in obstetrics often have high
rates of noncompliance. In this setting, the consequences of receiving epidural analgesia
are more important to clinicians and patients than the impact of being assigned to
epidural analgesia, thus the intention-to-treat (ITT) result is not a good estimate of the
consequence of receiving epidural analgesia due to noncompliance. Bannister-Tyrrell
et al. (2015) conducted an exploratory meta-analysis of the association between epidural
analgesia in labor and cesarean section by using the 9 trials, out of the 27 RCTs included
in the systematic review, that have full compliance data with non-zero events.
Data were recorded on treatment assignment r (r = 1 for epidural analgesia, r = 0 for
no/other analgesia in labor), actual received intervention t (t = 1 for epidural analgesia,
t = 0 for no/other analgesia in labor), and frequency of cesarean section o (o = 1 for yes,
o = 0 for no) by compliance with assigned intervention, where noncompliance describes
participants who were randomly assigned to receive epidural analgesia in labor but who
in fact received either another or no analgesia, or who were assigned to the control group
but ultimately received epidural analgesia in labor. Then for study i (i = 1, 2, ..., I),
the count Nirto denotes the number of patients in randomization group r who received
intervention t and had outcome o.
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Table 3.1: Data from randomized controlled trials of epidural analgesia in labor
Study Author, Year
Complete data Missing data
Allocated control Allocated epidural
Allocated control Allocated epidural

























1 Bofill, 1997 * 37 2 11 1 2 0 42 5 0 0 0 0
2 Clark, 1998 * 72 6 68 16 7 2 134 13 0 0 0 0
3 Dickinson, 2002 0 0 0 0 0 0 0 0 428 71 408 85
4 Evron, 2008 40 4 0 0 0 0 0 0 0 0 129 19
5 El Kerdawy, 2010 0 0 0 0 0 0 0 0 12 3 11 4
6 Gambling, 1998 0 0 0 0 206 10 371 29 573 34 0 0
7 Grandjean, 1979 0 0 0 0 0 0 0 0 59 1 30 0
8 Halpern, 2004 * 62 5 44 7 0 0 112 12 0 0 0 0
9 Head, 2002 * 51 7 2 0 3 0 43 10 0 0 0 0
10 Hogg, 2000 0 0 0 0 0 0 0 0 46 6 46 7
11 Howell, 2001 0 0 0 0 0 0 0 0 169 16 171 13
12 Jain, 2003 * 72 11 0 0 0 2 36 7 0 0 0 0
13 Long, 2003 0 0 0 0 0 0 0 0 44 6 29 1
14 Loughnan, 2000 0 0 0 0 0 0 0 0 270 40 268 36
15 Lucas, 2001 0 0 0 0 0 0 0 0 304 62 309 63
16 Muir, 1996 0 0 0 0 0 0 0 0 20 2 25 3
17 Muir, 2000 0 0 0 0 0 0 0 0 79 9 86 11
18 Nafisi, 2006 * 179 19 0 0 0 0 173 24 0 0 0 0
19 Nikkola, 1997 * 6 0 4 0 0 0 10 0 0 0 0 0
20 Philipsen, 1989 0 0 0 0 0 0 0 0 48 6 47 10
21 Ramin, 1995 * 546 17 95 8 230 2 393 39 0 0 0 0
22 Sharma, 1997 * 336 16 5 0 114 1 231 12 0 0 0 0
23 Sharma, 2002 0 0 0 0 11 1 199 15 213 20 0 0
24 Shifman, 2007 0 0 0 0 0 0 0 0 32 18 45 15
25 Thalme, 1974 0 0 0 0 0 0 0 0 10 4 8 6
26 Thorp, 1993 0 0 0 0 0 0 0 0 44 1 36 12
27 Volmanen, 2008 * 23 1 3 0 1 0 23 1 0 0 0 0
The * indicates that the corresponding study has complete data on compliance status.
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These RCTs varied in their inclusion criteria, labor management strategies, etc. In
the 27 RCTs, 4,459 women were assigned to receive epidural analgesia and 4,426 were
assigned to receive non-epidural or no analgesia. Complete data were available on the
cesarean outcome, with 470 cesarean deliveries in women assigned to epidural and 419
cesarean deliveries in women assigned to non-epidural or no analgesia.
However, complete data on the number of cesarean sections in the compliant and
non-compliant groups were available only for 10 studies, and data on noncompliance
status per randomization group were only partly available for 13 of the 27 RCTs. We
use t = ∗ to denote when the actually-received intervention is missing, then reorganize
the available complete data and marginal data in Table 3.1.1. If Nirto were available
for each t ∈ {0, 1}, the corresponding marginal count Nir∗o was assigned as 0; otherwise
if the actual received intervention data for arm r of study i were missing, only the
marginal data Nir∗o are shown in the table.
3.1.2 Analysis of Event Rates and Noncompliance Rates
Bannister-Tyrrell et al. (2015) estimated the association between epidural analgesia in
labor and cesarean section using ITT and IV analysis, including only the 9 studies
with complete data on the number of cesarean sections in compliant and noncompliant
participants. We want to test whether the studies with incomplete data provide extra
information. The ITT meta-analysis of the 27 RCTs gave a pooled Risk Ratio 1.10
(95% confidence interval: 0.97, 1.25; P=0.071) for cesarean section following epidural
analgesia in labor, which implies that epidural analgesia in labor is not associated with
risk of cesarean section. However, due to the high rate of noncompliance, an ITT
analysis may not be a good way to estimate the effect of receiving epidural analgesia.
The ITT pooled effect is potentially biased, especially when noncompliance cannot be
assumed to be random with respect to the outcome in the meta-analysis. Therefore, we
investigated the association between the ITT event rates and the noncompliance rates.
Because several studies had 0 events or 0 noncompliance, we used a bivariate generalized
linear mixed effects model (BGLMM) (Chu and Cole, 2006) to do the analysis on the
27 studies. The BGLMM assumes a bivariate normal distribution of probabilities in
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the two groups (p1i, p0i) in a transformed scale, where the probabilities can be either
event rates {p1i = P (oi = 1|ri = 1), p0i = P (oi = 1|ri = 0)} or noncompliance rates
{p1i = P (ti = 0|ri = 1), p0i = P (ti = 1|ri = 0), }, respectively. Specifically, the model
is a probit model with:
Φ−1(p1i) = u+ η1i, Φ
−1(p0i) = v + η0i, (η1i, η0i)
T ∼MVN(0,Ση). (3.1)
In this model, Φ(.) is the standard Gaussian density function, (η1i, η0i) are random




. We chose the probit link
because it has a closed-form formula for the overall probabilities E(p1i) = Φ(u/
√
1 + σ2u)
and E(p0i) = Φ(v/
√
1 + σ2v), based on Equation (3.1).
We did a Bayesian analysis using JAGS (Plummer, 2003) to draw Markov chain
Monte Carlo (MCMC) samples from the joint posterior distribution. We assigned vague
priors N(0, 1000) to the fixed effects u, v, and the commonly-used inverse Wishart dis-
tribution InvW (I, ν = 3) to the covariance matrix Ση, where I is the identity matrix.
The cesarean section event rates {p1i = P (oi = 1|ri = 1), p0i = P (oi = 1|ri = 0)}, and
the intervention noncompliance rates {p1i = P (ti = 0|ri = 1), p0i = P (ti = 1|ri = 0)}
were analyzed separately using the model in Equation (3.1). After 10,000 burn-in sam-
ples, 40,000 posterior samples were obtained. The overall estimates E(p1i), E(p0i) were
calculated using the closed form formula shown above. We write posterior medians fol-
lowed by 95% equal-tail credible interval (CI) in brackets for the rest of this chapter. The
overall probability of having a cesarean section in patients assigned to epidural analgesia
was estimated as 12.9% (9.9%, 17.0%), while in those assigned to no/other analgesia it
was 11.3% (8.5%, 15.0%). Also, the noncompliance rate in the epidural analgesia arm
E{P (ti = 0|ri = 1)} was 15.6% (5.4%, 29.0%), while while in the no/other analgesia
arm E{P (ti = 1|ri = 0)} was 13.8% (3.4%, 31.3%).
Figure 3.1 plots the study-specific posterior medians and 95% CIs for the cesarean
section event rates (horizontal lines) and the noncompliance rates (vertical lines) in both
the epidural analgesia arm (dashed line) and the control arm (solid line). Noncompliance
rates show somewhat different patterns in the two randomization groups: as the event
rate increases, the noncompliance rate tends to be higher, but this trend is more obvious
in the control groups. Arguably, the association is in the opposite direction for the
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treated groups.
Figure 3.1: Study-specific event rates vs. noncompliance rates in studies of epidural
analgesia in labor. Coordinates of each dot are the posterior medians of the study-
specific event rate and compliance rate. Horizontal lines represent the 95% CI of study-
specific posterior cesarean section event rate. Vertical lines represent the 95% CI of
study-specific posterior noncompliance rate. Dashed lines show results in the epidural
analgesia arm, while solid lines mark show results in no/other analgesia group. The
horizontal axis has a logarithmic scale.
Therefore, the relationship between these two rates motivates us to do a causal
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inference analysis on the treatment effects, rather than use the ITT analysis ignoring
noncompliance. However, the existing complier average causal effect (CACE) framework
needs complete information on compliance. With completely or partially missing data
on compliance in many studies, we need a new method to include these studies but
still give a valid causal interpretation. We introduce this method in Section 3.2 by first
defining essential notations and assumptions.
3.2 Statistical Methods
3.2.1 Definition of the Complier Average Causal Effect (CACE)
Notation
In a meta-analysis with I two-armed randomized trials, Ni is the number of subjects
in the i-th trial, where Ni0 represents those who are randomly assigned to the con-
trol/placebo group and Ni1 to the active treatment group. Let Rij = r index the
randomization assignment for subject j in study i with r = 0 for assignment to control
and r = 1 for assignment to treatment. Let T rij = t ∈ {0, 1} be the potential treat-
ment received under the randomization assignment r, where t = 1 indicates receiving
the active treatment and t = 0 placebo. Let Y r,tij = o ∈ {1, 2, . . . , O} be the potential
outcomes under randomization assignment r and treatment received t for the j-th sub-
ject in the i-th trial. Note that the sets of {Y r,tij } and {T rij} are the potential outcome
and treatment-received status under possible r and t, but for each subject in a trial,
only one of the possible values of each set can be observed. Therefore, we denote the
observed response and received treatment variables as Yij and Tij for the j-th subject
in the i-th trial. We allow Tij = ∗ if the actual received treatment is not recorded, and
Yij = ∗ if the outcome is not recorded for the j-th patient in the i-th study. Then we let
M i be the Ni-dimensional vector of missing indicators for all subjects in trial i, with
individual element Mij = m corresponding to whether subject j has actual treatment
received status on record (m = 0) or missing (m = 1).
Following Imbens and Rubin (1997), we let Cij be the latent compliance class of the
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j-th patient in the i-th trial, defined as follows:




ij) = (0, 0), i.e., subjects who would receive control
if randomized to either group;




ij) = (0, 1), i.e., subjects who would receive the inter-
vention to which they were randomized;




ij) = (1, 1), i.e., subjects who would receive active
treatment if randomized to either group;




ij) = (1, 0), i.e., subjects who would receive the interven-
tion opposite to their randomized assignment.
A subject’s compliance status Cij is not observable because in a two-arm trial, only
one of T 1ij and T
0
ij can be observed. Based on the observed randomization group and
actual treatment received, the compliance classes can only be partially identified (see
Table 3.2.1, columns Rij , Tij , and Cij).
Assumptions and Outcome Distributions
For each study, we make assumptions identical to those listed in Angrist et al. (1996):
Assumption 1: Stable unit treatment value assumption (SUTVA) (Rubin, 1980).
The outcome for a subject is unaffected by the particular assignments of treatments to
the other subjects. That is, if r = r′ then T rij = T
r′
ij ; and if r = r
′ and t = t′ then
Y r,tij = Y
r′,t′
ij .
Assumption 2: Random assignment to randomization groups. For all Ni subjects in
the i-th trial, the treatment assignment is random. This assumption implies that the
proportion of compliers should be the same in the intervention and control groups.
Assumption 3: Exclusion restriction. For subject j in the i-th trial, Y r,tij = Y
r′,t
ij
for all r, r′ and t, i.e., the randomization assignment affects responses only through its





for all r, r′ and t. Therefore, for always-takers and never-takers, the distribution of
outcomes does not depend on the randomization group.
Assumption 4: E[T 1ij − T 0ij ] 6=0 for each i. For each trial, we assume the fraction of
subjects who receive each intervention varies by randomization group.
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Assumption 5: Monotonicity. P [T 1ij ≥ T 0ij ] = 1 for each trial. This implies that no
subject necessarily receives the treatment opposite to the assignment, under assignment
to both active treatment and control. This assumption rules out the existence of de-
fiers, and reduces the number of compliance types for which we must derive estimates,
permitting a properly identified model.
Assuming randomized assignment and the exclusion restriction implies two restric-
tions: 1) the proportions of always-takers, never-takers and compliers in the control
group are equal to those in the treatment group; 2) for never-takers and always-takers,
the outcome distribution is the same under assignment to control and to active treat-
ment. With these two restrictions, for discrete outcomes o ∈ {1, . . . , O} we can ex-
tend the notation in Cheng (2009) and Baker (2011), and define the following pa-
rameters for latent compliance classes and response rates in the i-th study: 1) πia
and πin are the probabilities of being an always-taker and a never-taker, respectively,
so the probability of being a complier in the i-th study πic is 1 − πia − πin; 2) uio
is the probability of having outcome o for a complier randomized to the treatment
group, and vio is the probability for a complier randomized to the control/placebo
group in the i-th study; sio is the probability a never-taker has outcome o in the i-









o=1 bio = 1. Although latent compliance
classes cannot be fully identified based on randomization group (Rij) and observed
treatment received (Tij), the above two restrictions allow us to write the distributions
of observed Nirt in terms of the parameters for compliance classes and response rates,
where Nirt =
∑
j I(Rij = r, Tij = t) denotes the number of individuals in each ob-
served group. Let M(Nirt,xio) denote a multinomial distribution with Nirt subjects
and multinomial probabilities {xio}. The observed count for each outcome o in group
{j : Rij = r, Tij = t} is Nirto, o = 1, . . . , O. Table 3.2.1 shows the distribution of each
observed count in trial i, where qio =
πicvio+πinsio
1−πia and pio =
πicuio+πiabio
1−πin are probabilities
corresponding to Ni00o and Ni11o, o ∈ {1, . . . , O}.
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Table 3.2: Observed groups, latent compliance classes and outcome probabilities of trial
i
Rij Tij Cij Yij = o ∈ {1, . . . , O} Count
0 0 0 (never-taker) or 1 (complier) M(Ni00, qio =
πicvio+πinsio
1−πia ) Ni00o
0 1 2 (always-taker) or 3 (defier) M(Ni01, bio) Ni01o
1 0 0 (never-taker) or 3 (defier) M(Ni10, sio) Ni10o
1 1 1 (complier) or 2 (always-taker) M(Ni11, pio =
πicuio+πiabio
1−πin ) Ni11o
Defiers are ruled out by the monotonicity assumption.
Furthermore, according to the relations between observed groups and latent compli-
ance classes, we have
∑
oNi00o = Ni00 = Ni0(1−πia) and
∑
oNi01o = Ni01 = Ni0πia, so
the vector of observed counts in the control group (Ni001, . . . , Ni00O, Ni011, . . . , Ni01O)
follows a multinomial distribution M(Ni0, xi0 = (xi001, . . . , xi00O, xi011, . . . , xi01O)),
where xi00o = qio(1−πia) = πicvio+πinsio, xi01o = bioπia, and o ∈ {1, . . . , O}. Similarly,
in the active treatment group, the vector of observed counts (Ni101, . . . , Ni10O, Ni111, . . . ,
Ni11O) follows a multinomial distribution M(Ni1, xi1 = (xi101, . . . , xi10O, xi111, . . . ,
xi11O)), where xi10o = sioπin, xi11o = pio(1− πia) = πicuio + πiabio, and o ∈ {1, . . . , O}.
Let λi be the probability P (Rij = 1), which is usually known in a trial and treated
as fixed. Therefore, for study i (i = 1, 2, . . . , I), all observed counts Nirto follow a single
multinomial distribution, with corresponding probability Pirto, for r ∈ {0, 1}, t ∈ {0, 1},
o ∈ {1, . . . , O}. In mathematical notation, the distribution is M(Ni,xi = {Pirto}),
where Pi0to = (1− λi)xi0to and Pi1to = λixi0to.
In addition to Assumptions 1-5, we make the latent ignorable (LI) missing assump-
tion as described in Section 1.3. That is, given the observed data and the latent un-
observed compliance classes, missingness has no residual dependence on the outcomes.
Under the LI assumption, Table 3.2.1 summarizes a typical data structure and notation
for a study i with missing treatment-received status for randomized treatment group
r ∈ {0, 1}. In each cell of Table 3.2.1, the first row shows the count and the second
row shows the corresponding probability of the outcome; for a study in which subjects
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randomized to r had missing data on actual treatment received, only the rows labeled
“Missing” would be observed.
Table 3.3: Typical data for study i with missing actual treatment
received status in randomization group r ∈ {0, 1}
Treatment received
Outcome
1 . . . O
0
Nir01 . . . Nir0O
Pir01 . . . Pir0O
1
Nir11 . . . Nir1O
Pir11 . . . Pir1O
Missing
Nir∗1 . . . Nir∗O
Pir01 + Pir11 . . . Pir0O + Pir1O
In each cell, the first row: the observed count;
second row: the corresponding probability.
CACE in Meta-analysis
One causal effect of interest in many studies is the CACE discussed in Section 1.3. CACE
for the i-th two-arm trial is defined as θCACEi = E(Y
1
ij −Y 0ij |Cij = 1). The overall causal
effect θCACE from the meta-analysis can be estimated by taking the expectation of θCACEi
over all I trials, θCACE = E(θCACEi ). For an ordinal outcome Yij = o ∈ {1, . . . , O},
suppose we use equally spaced scores {1, 2, ..., O} to reflect the real distances between




o (o× vio). When the outcome is binary, we
let o ∈ {0, 1}, so the CACE for the i-th trial is θCACEi = ui1 − vi1.
A positive (negative) value of θCACEi indicates a beneficial treatment effect in the
i-th trial if a higher value of o means a better (worse) outcome, and θCACEi = 0 indi-
cates no causal effect of treatment for compliers. Besides the aforementioned equally
spaced scores {1, 2, ..., O}, their linear transforms may also be sensible in many cases
and provide a reasonable compromise (Agresti, 2003). Alternative scoring systems such
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as midranks are also possible. When uncertain about which scoring choice to use, a
sensitivity analysis can be conducted on different reasonable choices to see how they
affect the estimates.
3.2.2 Estimation and Inference
The Likelihood
Let Ni = {Nir} be the vector of observed data in study i, where r refers to the
randomization group (r = 1 for treatment and r = 0 for the control/placebo arm). In
each arm r, Nir = {Ncir,Nmir }, where the superscripts c and m denote complete and
marginal counts, respectively. Ncir = {Nirto} under each t ∈ {0, 1}, and o ∈ {1, . . . , O}.
If the full compliance data were observed in arm r of study i, the corresponding marginal
counts Nmir = {Nir∗o} are assigned as 0. Otherwise, if the actual received-treatment
status in randomization arm r of study i was missing, only the marginal data Nmir =
{Nir∗o} are available.
From Section 3.1.1, if full compliance data were observed in both randomization
groups, all observed counts Nirto follow a single multinomial distribution, with proba-
bility Pirto, where Pi0to = (1−λi)xi0to and Pi1to = λixi0to. Furthermore, as indicated by
Table 3.2.1, all Nir∗o also follow a multinomial distribution with probability Pir0o+Pir1o
if only marginal data were observed, for o ∈ {1, . . . , O} in the i-th trial. Therefore, defin-
ing βi = (πia, πin, si, bi,ui,vi), where si = (si1, . . . , si(O−1)), bi = (bi1, . . . , bi(O−1)),



















where the relations among the components of βi and Pirto are summarized in Section
3.2.1, j = 1, . . . , Ni, o = 1, . . . , O, and the indicator function I(Yij = o) = 1 if Yij = o








o bio = 1
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and 0 ≤ πia, πin, uio, vio, sio, bio ≤ 1. The likelihood function for all trials in a meta-
analysis is L(β) =
∏
i Li(βi).
We use trials with binary outcomes to further illustrate the modeling; this also
represents the situation in the motivating example. In this case, o ∈ {0, 1}, i.e., si0 +
si1 = bi0 + bi1 = ui0 + ui1 = vi0 + vi1 = 1 for study i, so the vector parameters of
si, bi,ui,vi are reduced to si1, bi1, ui1, vi1. Data can be arranged as shown in Table
3.1.1, where in each randomization arm, data are shown either in the column “Complete
data” or in the column “Missing data”, with values in the other columns all 0. Thus
the observed data are Nir = {Ncir,Nmir } = {Nir00, Nir01, Nir10, Nir11, Nir∗0, Nir∗1} for
r ∈ {0, 1}. Then the likelihood contribution for the i-th trial can be written as
Li(βi) = [(1− λi){πic(1− vi1) + πin(1− si1)}]
Ni000{(1− λi)(πicvi1 + πinsi1)}Ni001
{(1− λi)πia(1− bi1)}Ni010{(1− λi)πiabi1}Ni011{λiπin(1− si1)}Ni100
{λiπinsi1}Ni101 [λi{(πic(1− ui1) + πia(1− bi1)}]Ni110{λi(πicui1 + πiabi1)}Ni111
[(1− λi){πic(1− vi1) + πin(1− si1) + πia(1− bi1)}]Ni0∗0{(1− λi)(πicvi1 + πinsi1 + πiabi1)}Ni0∗1
[λi{πic(1− ui1) + πia(1− bi1) + πin(1− si1)}]Ni1∗0{λi(πicui1 + πiabi1 + πinsi1)}Ni1∗1
(3.3)
where βi = (πia, πin, si1, bi1, ui1, vi1), and the parameters vary between studies following
some distributions with hyper-parameters, which we now describe.
To account for potential between-study heterogeneity of the compliance classes and
outcome probabilities, we consider a random effects model. Specifically, to guarantee
the desired properties of latent compliance classes in study i, i.e., πin + πia + πic = 1
and 0 ≤ πin, πia, πic ≤ 1, and to allow these probabilities to vary between studies,







ni = αn + δin, ai = αa + δia. The random effect (δin, δia) has a bivariate normal





correlation between ni and ai.
We also define random effect models on the transformed scale of each response
probability si1, bi1, ui1, vi1: g(si1) = αs+δis, g(bi1) = αb+δib, g(ui1) = αu+δiu, g(vi1) =
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αv + δiv, where g(·) is a link function such as the logit or probit. These response rates
are assumed to be independent across principal strata, so δis ∼ N(0, σ2s), δib ∼ N(0, σ2b ),
δiu ∼ N(0, σ2u), δiv ∼ N(0, σ2v). The model can easily be extended to more general cases
with more than binary outcomes.
Prior Specifications and the Posterior Distribution
We assign proper but diffuse prior distributions for the hyper-parameters. Specifically,
αn and αa both follow N(0, 2.5
2), such that under the simplest situation (a fixed ef-
fects model), a 95% prior probability interval for any of the probabilities πin, πia, πic
ranges from about 0.001 to 0.91; and αs, αb, αu, αv all follow N(0, 2
2), which implies a
95% interval for the probabilities si1, bi1, ui1, vi1 ranging from about 0.01 to 0.98. The






v are assumed to be
Gamma(2, 2), which corresponds to a 95% interval of (0.6, 2.9) for the corresponding
standard deviations, allowing moderate heterogeneity in the response probabilities. The
prior for the precision matrix Σ−1lc is Wishart, i.e., W (I, 3), where I is the identity ma-
trix. In a reduced model with one of σ2n, σ
2
a set to 0, the prior of the other precision
parameter is also assumed to be Gamma(2, 2), which gives moderate heterogeneity for
latent compliance classes probabilities.
Let function f(βi|β0,Σ0) be the distributions described in Section 3.2.2 of all pa-
rameters βi = (πia, πin, si1, bi1, ui1, vi1), where β0 refers to the vector of mean
hyper-parameters (αn, αa, αs, αb, αu, αv), and Σ0 is the covariance matrix of hyper-








v . Denoting the prior distributions specified
above as f(β0) and f(Σ0), the joint posterior distribution is then proportional to∏
i Li(βi)f(βi|β0,Σ0)f(β0)f(Σ0). We sample from the joint posterior using Markov
chain Monte Carlo (MCMC) methods, specifically Gibbs and Metropolis-Hastings sam-
pling algorithms (Gelfand and Smith, 1990).
As mentioned in Section 3.2.1, for binary outcomes, θCACE can be estimated as














)dt, where φ(·) is the standard Gaus-
























)dt does not have a closed-form formula, it has a well-
established approximation, E(si1) ≈ logit−1( αs√
1+C2σ2s
), where C = 16
√
3
15π (Zeger et al.,
1988). This approximation also applies to estimating the overall always-taker response
rate E(bi1).
In each MCMC iteration, draws of θCACE are calculated from the MCMC draws
using Equation (3.4). We use medians and equal-tail credible intervals (CIs) of these
posterior samples to make inferences for the random effects models.
Model Selection and Implementation
The model specified in Section 3.2.2 included all possible random effects to account for
possible between-study heterogeneity of the fractions in the compliance classes and of the
response rate probabilities. However, over-fitting the data with too many random effects
should be avoided because it may inflate posterior variances. Therefore, we have used a
forward selection procedure to choose the final model, beginning with a model having
no random effects and at each forward step adding the random-effect component that
gave the largest improvement in the deviance information criterion (DIC) (Spiegelhalter
et al., 2002). Other model-selection approaches can be substituted easily, e.g., using a
different model-selection criterion or a different search strategy.
We used JAGS software version 4.3 via the rjags package in R to sample from the
joint posterior distribution. We ran three independent MCMC chains with starting
points drawn randomly from their prior distributions. After 10,000 burn-in samples,
the subsequent 100,000 posterior samples were obtained for each chain. Convergence to
the stationary distribution was assessed using trace plots, sample autocorrelation, and
the Gelman and Rubin statistic (Gelman and Rubin, 1992).
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Model for Complete Data Only
Here we discuss how the naive “two-step” approach introduced in Section 1.3 can be
viewed as a special case of our model using only trials with complete noncompliance
data. In this situation, only trials with complete data Ncir = {Nirto} are used to make
















Note that when Mij = 1 (i.e., for trials with incomplete noncompliance data), Li(βi) =
0. Thus for trial i with complete noncompliance data Ncir = {Nirto}, one can separately
estimate θCACEi and obtain a standard error. One can then combine these study-specific
estimates using a standard meta-analysis method, such as a fixed-effect or random ef-
fects model, to estimate the population-averaged CACE. Alternatively, one can obtain
the posterior estimate of θCACE through the joint posterior distribution, which is propor-
tional to the likelihood for trials with complete noncompliance data L(β) =
∏
i Li(βi)
multiplied by the prior distributions. Note that by Lin and Zeng (2010), the two-step
approach can be viewed as asymptotically equivalent to the model maximizing the joint
likelihood. Therefore, in the simulation section below, we compare the performance of
our proposed model including all trials with a model using only trials with complete
noncompliance data instead of a two-step frequentist approach.
3.3 Case Study Results
3.3.1 Model Selection Results
We estimated the CACE of epidural analgesia in labor on cesarean section by including
all of the 27 RCTs introduced in Section 3.1. Although the full model has 6 potential
random effects in total, δin, δia, δis, δib, δiu and δiv, we adopted the forward selection pro-
cedure described in Section 3.2.2. Table 3.3.1 presents DIC, DIC improvement, and the
effective number of parameters (pD) for each model considered in the forward selection
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procedure. Starting with the model that includes no random effects (called Model I),
the largest improvement was obtained by adding a random effect for the study-specific
probability of being an always-taker, i.e., δia, called Model IIf. In the next step, adding
a random effect for the probability of being a never-taker, δin (Model IIIe), reduced DIC
the most. This revealed an important characteristic of this meta-analysis: the studies
might vary considerably in their recruitment criteria, study procedures, beliefs of the
local PIs, etc., so that properties of the latent compliance classes vary between studies.
The next forward step produced a meaningful improvement by including a random effect
for the cesarean section rate of a never-taker, si1 (Model IVa). For the fourth forward
step, DIC was improved most by adding one more random effect, the probability of
having a cesarean section for a complier in the randomized treatment group, δiu (Model
Vc). This improvement was modest compared with the previous step, but still notable
(DIC decreased by 6.7 points compared with Model IVa). It is difficult to say what con-
stitutes an important improvement in DIC; we follow Lunn et al. (2012) in considering
that a reduction of less than 5 is not a substantial improvement. The final step found
no notable improvements from including additional random effects. Therefore, the final
model was Model Vc, including random effects δia, δin, δis, and δiu.
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Table 3.4: Selecting random effects using a forward selection procedure
for the epidural analgesia in labor meta-analysis
Random effects models DIC DIC improvement pD
Model I (None) 1409.0 N/A 6.8
Model IIa (δis) 1225.2 183.8 36.1
Model IIb (δib) 1258.5 150.5 33.2
Model IIc (δiu) 1325.9 83.1 25.6
Model IId (δiv) 1321.4 87.6 27.0
Model IIe (δin) 992.5 416.5 89.6
Model IIf (δia) 814.2 594.8 26.2
Model IIIa (δia, δis) 748.3 65.9 45.0
Model IIIb (δia, δib) 781.8 32.4 37.0
Model IIIc (δia, δiu) 790.9 23.3 37.6
Model IIId (δia, δiv) 804.6 9.6 39.2
Model IIIe (δin, δia) 508.2 306.2 33.3
Model IVa (δin, δia, δis) 464.3 43.9 46.2
Model IVb (δin, δia, δib) 490.7 17.5 41.6
Model IVc (δin, δia, δiu) 494.3 13.9 47.7
Model IVd (δin, δia, δiv) 514.4 -6.2 49.1
Model IVe (δin, δia, ρ) 507.8 0.4 34.0
Model Va (δin, δia, δis, ρ) 465.4 -1.1 46.9
Model Vb (δin, δia, δis, δib) 465.1 -0.7 49.9
Model Vc (δin, δia, δis, δiu) 457.7 6.7 59.9
Model Vd (δin, δia, δis, δiv) 478.0 -13.7 60.3
Model VIa (δin, δia, δis, δiu, δib) 457.1 0.6 62.9
Model VIb (δin, δia, δis, δiu, δiv) 465.9 -8.2 70.2
Bold-face cells are models selected using the forward selection procedure.
DIC improvement is the reduction in DIC compared to the previous step’s
lowest DIC.
The study-specific component corresponding to each random effect: δis
never-taker response, δib always-taker response, δiu treated complier re-
sponse, δiv control complier response, δin never-taker probability, δia
always-taker probability; ρ is the correlation between δia and δin.
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Figure 3.2: Posterior distributions of θCACE of epidural analgesia in labor on cesarean
section, the kernel smoothed density estimate from 100,000 Monte Carlo samples.
Figure 3.2 shows the kernel-smoothed posterior density of θCACE from the Bayesian
hierarchical models selected in each forward step. The plot suggests a fairly symmet-
ric posterior density of θCACE for all models. After adding the random effect δiu to
probit(ui1) in Model Vc, the posterior of θ
CACE is shifted right and its variance in-
creased considerably, which further indicates the importance of appropriate accounting
for random effects.
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Table 3.5: Summary of parameter estimates for the epidural analgesia meta-analysis
Parameter Model I(None) Model Vc(δin, δia, δis, δiu)
θCACE −0.0030.0170.038 −0.0030.0410.105
Overall never-taker probability πn 0.2140.2300.246 0.0330.1010.259
Overall always-taker probability πa 0.1360.1520.170 0.0650.1900.400
Overall complier probability πc 0.5940.6180.641 0.5440.6870.787
Overall never-taker response s1 0.0290.0460.068 0.1160.2540.488
Always-taker response b1 0.1240.1680.216 0.1000.1400.174
Treated complier response u1 0.0930.1120.131 0.0650.1080.173
Control complier response v1 0.0780.0950.112 0.0540.0680.083
Mean parameter of ni −1.089-0.988−0.887 −3.196-2.173−1.224
Mean parameter of ai −1.542-1.399−1.260 −3.521-2.038−0.758
Standard deviation of ni – 1.0551.6452.846
Standard deviation of ai – 1.4022.2403.901
Standard deviation of logit(si1) – 1.2312.1104.131
Standard deviation of probit(ui1) – 0.4310.6000.912
The notation LPU denotes the posterior median P with 95% equal tailed credible limits
(L, U).
Table 3.3.1 lists estimated parameters from the fixed effects model (Model I) and
the final model (Model Vc), where the triple of percentiles, 2.55097.5, is used to display
each parameter’s posterior median with its 95% equal tail credible interval, as suggested
by Louis and Zeger (2009). Monte Carlo integration (Ueberhuber, 1997) was used to
estimate the overall probabilities of being in each principal stratum, πa, πc, and πn when
δin and δia were both present (Model Vc). The overall never-taker response rate s1 =






15π , and the overall treated complier response rate u1 = E(ui1) was estimated
using the closed-form formula E(ui1) = Φ(
αu√
1+σ2u
). For other overall response rates
(e.g., b1, v1), the values were directly estimated by transforming back the fixed-effect
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parameters if the probabilities were assumed to be the same across studies according to
either Model I or Model Vc. For example, the overall always-taker response rate was b1 =
E(bi1) = logit
−1(αb) because bi1 had no random effect in either model. Based on the final
model (Model Vc), the posterior median and interval for θCACE were −0.0030.0410.105,
which covers zero and indicates a nonsignificant complier average causal effect, but the
estimated effect was about 2 that estimated by the fixed effect model (Model I). The
random effects for πa, πn, and πc on the transformed scale had standard deviations of
1.65 and 2.24, while the random effect for s1 had a standard deviation of 2.11 on the
logit scale. After adding random effects for δin, δia, δis and δiu, the posteriors of πn, πa,
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Figure 3.3: Forest plot of θCACE of epidural analgesia in labor on cesarean section.
The center of each square and the horizontal lines represent the posterior median and
95% equal tail credible interval of θCACEi for each study from the final model, Model
Vc. The diamond indicates the pooled estimate of θCACE and its 95% credible interval.
The symbol * indicates that the study has complete data on compliance status. With
complete data, a solid horizontal line is used to represent the posterior 95% CI of θCACEi ,
whereas a dashed line is used to show the CI for a study with incomplete compliance
data.
Figure 3.3 is a forest plot of the posterior medians and 95% equal-tail credible
intervals of θCACEi for each trial based on the final model, Model Vc. Studies with a
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“*” in the “Study (Author, Year)” column had complete data on compliance status and
we used solid horizontal lines to represent their corresponding CIs. For a study with
incomplete data, as its θCACEi was not directly estimable by the single trial, we used a
dashed line to show the posterior 95% CI. The figure showed that studies with complete
data tend to have shorter credible intervals, while the study-specific estimates θCACEi
were quite heterogeneous, indicating differences in the study populations. The overall
θCACE from the final model was not significant.
3.3.2 Sensitivity to the LI Assumption
The above models were built upon the assumption of latent ignorable (LI) missingness.
However, this assumption may not be satisfied in some applications. For example,
studies showing a treatment effect may have a higher chance of reporting compliance
status. This is a form of missing not at random (MNAR): the probability of missing
compliance data depends on the outcome measure. However, in practice, one can never
tell from the data at hand whether missingness is LI or MNAR (Little and Rubin, 2014).
Thus, we present a sensitivity analysis that incorporates a known MNAR mechanism
to see its impact on treatment-effect estimates.
Let the I × 2 matrix Ξ denote the study-level compliance missingness of a meta-
analysis dataset containing I studies and 2 treatment arms. The entries of Ξ are ξir,
i = 1, . . . , I and r = 0, 1, such that ξir = 1 if compliance information is missing in
randomized group r of study i, and ξir = 0 if the data is complete. We assume ξir ∼
Bern(pmisir ), where p
mis
ir is the probability of missing compliance status (i.e., no data on
the actual treatment taken) in study i’s randomized group r. We specify a model of
missingness for pmisir as
logit(pmisi0 ) = γ00 + γ10 × logit(vi1), logit(pmisi1 ) = γ01 + γ11 × logit(ui1), (3.6)
In this model, γ00 (γ01) is an unknown scalar parameter, and γ10 (γ11) describes
the strength of association between the missingness probability and the study-specific
response rate of a complier in the randomized control (treatment) group, i.e., the compo-
nents of θCACEi . When γ1r = 0 for r = 0, 1, the missingness probabilities are not related
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to any model parameters, hence the missingness is completely at random (MCAR). For
the purpose of assessing the effect of MNAR, for some given γ10 and γ11, this model of
missingness can be incorporated in the likelihood in Section 3.2.2 and treated as if it is
known to be true. Note that the model of missingness described here is not for general
MNAR scenarios, but is specific for the CACE problem, and we only consider scenarios
in which missingness is related to components of θCACE.
In this case study, as the random effect δiv was not selected into the final Model
Vc, the response rates for compliers randomized to the control group (vi1) were the
same across trials. Thus the missing probabilities in the control arm pmisi0 according to
Equation (3.6) were also the same for all studies i. For illustration, we set γ10 = 0 in
conducting sensitivity analyses to the specific MNAR scenario, to explore the impact on
CACE estimates as γ11 changes from negative to positive. Since a flat prior for γ0r with
a large variance would lead to a marginal prior distribution for pmisir heavily weighted
towards 0 and 1, we follow Zhang et al. (2017) by specifying a logistic(0, 1) prior for
γ0r, which gives an approximate uniform prior for p
mis
ir on (0, 1).
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Figure 3.4: Posterior of θCACE of the epidural analgesia in labor meta-analysis under
the assumption that the missingness probability in the treatment arm pmisi1 is linearly
related to ui1 on the logit scale. Bold solid line: posterior median; fine solid lines: 95%
equal-tail credible interval; fine dashed lines: 95% highest posterior density credible
interval. The fine dotted horizontal line is θCACE = 0.
Figure 3.4 summarizes the posterior of θCACE from the meta-analysis of epidural
analgesia in labor when we set γ01 = 0 in Equation (3.6) and allowed γ11 to range
from −2.5 to 2.5 under the final model (Model Vc). As γ11 increased from -2.5 to
2.5, the posterior median of θCACE increased from about 0.02 to 0.07, and the 95%
credible interval of θCACE no longer covered zero when the coefficient of logit(ui1) was
over about 0.5. That is to say, when the missingness probabilities were positively and
strongly enough correlated with ui1, the CACE became statistically significant, which
differs from the conclusion drawn in Section 3.3.1 under the LI assumption. Therefore,
the missingness mechanism for compliance would influence the causal effect estimates
51
in this epidural analgesia in labor meta-analysis.
3.4 Simulation
3.4.1 Simulation Setups
Simulation studies were conducted to evaluate how the proposed method performs under
different assumptions. As in the case study, we assumed o ∈ {0, 1}, i.e., the outcome
is binary. We set (αn, αa, αs, αb, αu, αv) = (−0.4,−0.6, 0.5,−0.5,−0.5, 0.5), so that the
true values in the absence of random effects were πic = 0.45, πin = 0.30, πia = 0.25
and θCACEi = −0.38. When random effects were present, we assumed the random
effects had standard deviation 0.5, i.e., each of σn, σa, σs, σu = 0.5. To evaluate the
model’s performance and the impact of random effects, we generated compliance status
and outcomes data with three sets of random effects, corresponding to Section 3.3.1’s
Model IIIe (δin, δia), Model IVa (δin, δia, δis), and Model Vc (δin, δia, δis, δiu). Under
each scenario, we simulated 2000 datasets. Each dataset comprised 20 studies where
350 subjects per study were randomized to either the treatment or control group with
a 1 : 1 ratio (λ = 0.5).
We created partially missing compliance data under the MCAR, LI, and MNAR
assumptions, as follows. Under the MCAR assumption, the missing indicators for all
studies were prespecified such that the first ten studies in the control arm (R = 0), and
the 6-th to the 15-th studies in the treatment arm (R = 1) did not have compliance
information, so that only 5 studies had full data in both arms. To generate partially
incomplete data under the LI and MNAR assumption, we applied a logit model to
calculate the missingness probabilities in the control arm (R = 0) and treatment arm
(R = 1) separately, which were used to generate the random missingness indicators to
keep only the marginal data in that arm of the study. The models for the missingness
indicators are:
ξir ∼ Bern(pmisir ),
LI: logit(pmisir ) = β0r + β1r × logit(πic)
MNAR: pmisi0 = 0.5, logit(p
mis
i1 ) = γ01 + γ11 × logit(ui1),
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where r = 0, 1 indicate the control and treatment groups respectively. If the missing
indicator ξir = 1, then data on compliance status in the i-th study arm r were set to
be missing, i.e., only marginal values Nir∗1, Nir∗0 were available. Our model settings
imply that the parameter πic is independent of θ
CACE
i , so we considered the missing
assumption to be LI. For ease of presentation, we let pmisi0 = p
mis
i1 in the LI scenario so
β0r and β1r can be reduced to β0 and β1. For MNAR, we assumed the probability of
missing compliance data in the treatment arm is related with ui1.
The intercept terms were chosen to control the expected missingness probability at
about 0.5 in each scenario. Under the LI assumption, we set β1 = 2, referring to the
scenario in which the missingness probabilities depend on the probability of being a
complier. In a study with a higher proportion of compliers, the noncompliance rates
tend to be smaller such that the ITT analysis would perform well. Thus, it may imply
a higher probability of not reporting compliance information. Thus the coefficient β1
was set to be a positive value, matching the above situation.
Under the MNAR assumption, we set γ11 = −2 to produce a scenario in which the
missingness in the treatment arm is related to the response rate in the compliers, while
the missing probability in the control arm was set to be a fixed value of 0.5. As the
true value of θCACEi in our setting is negative (a beneficial complier average causal effect
if the outcome o = 1 is an adverse event), we therefore created a scenario with: 1) a
fixed response rate for a control complier (vi1); and 2) a decreasing response rate as
ui1 increases in the treated complier. Thus, the beneficial CACE tended to be more
significant such that it was more likely that the study’s investigators would not report
compliance information. To do this, we set the coefficient γ11 to be negative. The value
γ11 = −2 implies a reasonable strength of the association between pmisi1 and ui1.
Under each missingness assumption and each true random-effect model, we compare
the performance of our proposed method with the naive approach (described in Section
3.2.2) that includes only studies with complete data. Note that to create the missing
compliance data, we just added Nir11 and Nir01 up to create the marginal Nir∗1, and
added Nir10 and Nir00 up to give Nir∗0. For the analyses using the data from all studies,
as no studies were discarded so the true underlying parameters are still in effect, and
53
the proposed approach can be robust to different missing data generating mechanisms.
However, for the naive approach that only includes studies with complete compliance
information, patterns of missing mechanism are expected to have an impact on the
results.
We used a model selection procedure in the simulation, fitting each dataset with all of
the following candidate models: 1) no random effect; 2) random effects only on (δin, δia);
3) random effects on (δin, δia, δis), and 4) random effects on (δin, δia, δis, δiu), and we
counted the frequency of selecting each model using DIC. Note that either πic or ui1 must
be generated with a random effect to ensure the missingness probabilities vary across
studies. Thus under LI, we generate data with random effects (δin, δia), (δin, δia, δis),
and (δin, δia, δis, δiu), and under MNAR we generate data with (δin, δia, δis, δiu).
3.4.2 Simulation Results
Table 3.4.2 summarizes results from the simulation studies regarding θCACE, comparing
the two approaches in terms of relative bias (ReBias), mean square error (MSE), 95%
credible interval coverage probability (CP), 95% credible interval length (CIL), and rel-
ative efficiency (RelEff), defined as MSE from the naive analysis including studies with
complete data only divided by MSE using the proposed model. Under each missingness
mechanism considered, we fit the model including the same random effects as in gener-
ating the data. Under the different missingness assumptions, the proposed models were
shown to provide nearly unbiased estimates for θCACE with smaller MSE. Generally,
the estimates were slightly biased when the data were generated under LI or MNAR
compared to MCAR, or as the number of random effects increased. The coverage prob-
abilities remained close to or above the nominal level 0.95 in all scenarios. The naive
method that discards studies with incomplete data also performed reasonably well with
no or trivial bias. When data were generated under the MCAR or LI missingness mech-
anism, though our proposed method was more efficient with consistently smaller MSE
and shorter 95% credible interval length, as it gained efficiency by including information
from more studies. However, when data were generated with missingness probabilities
that were strongly associated with one component of θCACEi (the MNAR assumption),
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the naive approach using only studies with complete compliance data had substantially
large relative bias and MSE. Moreover, the relative efficiency values were greater than
two in all scenarios, providing evidence that our proposed model is much more efficient
than simply discarding studies without complete compliance data.
Table 3.6: Simulation results: relative bias (ReBias), mean square error (MSE), 95% CI coverage probabil-
ities (CP), and 95% credible interval length (CIL) for θCACE
Missing Random Model inclucing all studies On studies with complete data
ReEff
Mechanism Effects ReBias MSE CP CIL ReBias MSE CP CIL
MCAR
None 0.003 0.001 0.951 0.106 0.006 0.003 0.957 0.202 3.599
δin, δia 0.017 0.001 0.969 0.133 0.018 0.002 0.960 0.198 2.294
δin, δia, δis -0.013 0.001 0.953 0.134 -0.001 0.003 0.952 0.200 2.432
δin, δia, δis, δiu 0.010 0.002 0.988 0.240 -0.087 0.007 0.993 0.455 3.022
LI,
β1 = 2
δin, δia 0.046 0.001 0.950 0.142 0.008 0.003 0.957 0.219 2.204
δin, δia, δis 0.030 0.001 0.963 0.142 0.003 0.003 0.951 0.217 2.627
δin, δia, δis, δiu 0.065 0.004 0.961 0.247 -0.066 0.008 0.989 0.445 2.321
MNAR,
γ11 = −2 δin, δia, δis, δiu -0.022 0.003 0.978 0.241 -0.319 0.021 0.945 0.507 7.493
ReBias = Bias/True Value
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Table 3.7: The estimated probability of selecting a candidate model as the final model using DIC,
based on simulation studies with 2000 replicates
Missing True Random Selected Random Effects Model
Mechanism Effects Model None δin, δia δin, δia, δis δin, δia, δis, δiu
MCAR
None 98.7 1.2 0.1 0
δin, δia 0 94.6 4.85 0.55
δin, δia, δis 0 2.8 95.0 2.2
δin, δia, δis, δiu 0 0.05 1.0 98.95
LI, β1 = 2
δin, δia 0 95.65 4.2 0.15
δin, δia, δis 0 2.9 94.9 2.2
δin, δia, δis, δiu 0 0.4 1.8 97.8
MNAR,
γ11 = −2 δin, δia, δis, δiu 0 0.02 1.45 98.35
Bolded cell are the probability of identifying the correct model. The probabilities have been multiplied
by 100 for presentation. MCAR: missing completely at random, LI: latent ignorable, MNAR: missing
not at random.
Under each missing mechanism and true data generating model, we fit four candidate
models with different numbers of random effects as described in Section 3.4.1. Table
3.4.2 summarizes the frequency of selecting each candidate model as the “best” model
in each set of simulations. For all data-generating scenarios, DIC had a probability
around 0.95 of identifying the true random effects model. The results indicate that the
Bayesian hierarchical models account for the uncertainty in estimation and produce an
appropriate selection of random effects even under the MNAR missing mechanism.
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Table 3.8: Performance of estimates and credible intervals for θCACE for each model,
based on 2000 simulated datasets
Missing Random Effects Random Effects in Models
Mechanism Generating Data None δin, δia δin, δia, δis δin, δia, δia, δiu
MCAR
None
ReBias 0.006 0.005 -0.021 0.023
MSE 0.001 0.001 0.001 0.001
CP* 0.953 0.972 0.968 0.998
CIL** 0.106 0.129 0.126 0.210
δin, δia
ReBias 0.012 0.005 -0.020 0.025
MSE 0.002 0.001 0.001 0.001
CP 0.847 0.961 0.955 0.997
CIL 0.110 0.133 0.132 0.220
δin, δia, δis
ReBias 0.010 -0.007 -0.013 0.035
MSE 0.002 0.001 0.001 0.002
CP 0.836 0.922 0.956 0.996
CIL 0.110 0.132 0.133 0.221
δin, δia, δis, δiu
ReBias 0.012 0.086 0.097 0.011
MSE 0.003 0.006 0.006 0.003
CP 0.680 0.637 0.664 0.978
CIL 0.110 0.142 0.148 0.239
LI, β1 = 2
δin, δia
ReBias 0.067 0.048 0.020 0.093
MSE 0.002 0.002 0.001 0.003
CP 0.795 0.938 0.959 0.978
CIL 0.118 0.143 0.141 0.231
δin, δia, δis
ReBias 0.066 0.040 0.031 0.101
MSE 0.002 0.002 0.001 0.003
CP 0.799 0.920 0.959 0.979
CIL 0.118 0.142 0.142 0.231
δin, δia, δis, δiu
ReBias 0.075 0.134 0.147 0.071
MSE 0.004 0.007 0.007 0.004
CP 0.669 0.620 0.625 0.966
CIL 0.118 0.152 0.158 0.248
MNAR,
γ11 = −2 δin, δia, δis, δiu
ReBias 0.001 -0.071 -0.029 -0.022
MSE 0.003 0.004 0.004 0.003
CP 0.668 0.671 0.748 0.983
CIL 0.111 0.129 0.139 0.241
Bold-face cells are the correct model. **CP: 95% credible interval coverage probability.
*CIL: 95% equal-tail credible interval length.
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Table 3.4.2 shows the relative bias (ReBias), mean square error (MSE), 95% credible
interval coverage probability (CP), and 95% credible interval length (CIL) for θCACE
fitting the four candidate models under each data generating scenario. We present
this table to check the performance of our proposed method when fitting the correct
model, as well as models that over-fit (including a random effect when it is not present),
and under-fit (omitting a random effect when it is present). Regardless of the missing
mechanism, when data were fit by a model with the right random effects, the estimated
θCACE generally had a small relative bias, and the coverage probability was around the
95% nominal level. In general, over-fitting produced slightly biased point estimates of
θCACE. Also, 95% credible intervals tended to become too wide as more random effects
were included in the model. This is especially true when δiu was added, which was
expected because δiu directly adds variability to θ
CACE
i . Regarding the 95% credible
interval coverage probabilities: 1) under the correct model or an over-fitting model, the
coverage probabilities were close to or greater than the nominal 0.95; and 2) under an
under-fitting model, failure to include the random effect for the study-specific response
rate of a never-taker (δis) did not affect the coverage probability notably, but failure
to include the random effect for the probability of the latent compliance groups (δin or
δia), or the study-specific response rate of a treated complier (δiu) reduced coverage for
θCACE substantially.
The results indicated that random effects should be selected carefully to account
for potential between-study heterogeneity when estimating CACE in a meta-analysis.
For the model performance in terms of the posterior estimates of θCACE under different
missing assumptions, no notable differences were identified, which was expected because
of the way we generated missing compliance data. As noted in Section 3.4.1, we did
not discard any study under either LI or MNAR, but just combined the generated data
from corresponding table cells with affected compliance status to create marginal total
counts. This did not affect the point estimates of parameters though it did reduce the
efficiency of estimates produced by our proposed models.
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3.5 Discussion
We proposed a Bayesian hierarchical model to estimate CACE in meta-analysis of RCTs,
accounting for both heterogeneous and incomplete noncompliance among studies, and
we applied it to a case study of epidural analgesia trials. We conducted simulation stud-
ies to evaluate the performance of our approach under different missingness mechanisms,
and the impact of misspecification of random effects. To the best of our knowledge, this
is the first meta-analysis of RCTs estimating CACE while adjusting for incomplete
noncompliance data.
Using the proposed method, all 27 epidural analgesia trials are included in the CACE
meta-analysis. Including information from studies with incomplete data may introduce
more heterogeneity into the meta-analysis and may affect the CACE estimate. The
simulations indicated that 1) our approach had a good chance of identifying the correct
model, and 2) our proposed model had better efficiency for estimating CACE, with
smaller MSE and shorter credible intervals, compared to the model only using trials
with complete compliance data. Our simulations under the MNAR assumption did
not discard any studies when fitting the proposed models, so we expected they would
still give unbiased CACE estimates. Nevertheless, the naive approach including only
studies with complete compliance data gave biased estimates, which was not surprising
because the studies with complete data are no long representative for all studies under
the MNAR missing mechanism.
Besides handling the situation in which some studies in a meta-analysis do not
report compliance information, the proposed method can be extended to handle missing
outcomes. Missing outcome data in RCTs commonly happens when researchers do not
collect follow-up outcome for some subjects. For example, consider a trial in which
patients randomized to the treatment group were encouraged to receive a flu shot, but
the patients themselves decided whether to receive flu shots, and their actual treatment
received was recorded. For the outcome of flu-related hospitalization, missing outcomes
could occur if some patients had the flu but were treated at hospitals not participating
in the study, or if some patients simply had unknown hospitalization status. In this
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case, we can extend the likelihood in Equation (3.2) by adding a column “missing” to
the right of Table 3.2.1, and the corresponding probabilities would be the sum of the
probabilities of all cells in that row.
Recently, extensions of models estimating CACE with missing data in a single study
have been developed. Specifically, Chen et al. (2009) discussed the identifiability and es-
timation of CACE under a nonignorable missing mechanism; Peng et al. (2004) proposed
an extended general location model to estimate the CACE with missing data in the out-
come and in baseline covariates. Estimating CACE with missing data in longitudinal
and survival outcomes has also been discussed (Yau and Little, 2001; Yang et al., 2012).
These methods have been proposed only for the single-study setting; potential exten-
sions for estimating CACE in meta-analysis await further development. Furthermore,
as network meta-analysis expands the scope of a conventional pairwise meta-analysis to
simultaneously compare multiple treatments by synthesizing both direct and indirect
information (Lumley, 2002; Zhang et al., 2014), extending the CACE meta-analysis




Estimating Causal Effect using
the Bayesian Method with the R
Package BayesCACE
This chapter introduces the R package BayesCACE, which performs CACE analysis for
binary outcomes in a single study, and meta-analysis with either complete or incomplete
noncompliance information. This package is currently available from GitHub at https:
//github.com/JinchengZ/BayesCACE. It uses Markov chain Monte Carlo (MCMC)
methods on the R platform through JAGS. JAGS is a program for analyzing Bayesian
hierarchical models using MCMC simulation, which is available for diverse computer
platforms including Windows and Mac OS X. Convergence of the MCMC routine can be
assessed by the function outputs. The package also provides functions to make posterior
trace plots, density plots, and auto-correlation plots. For meta-analysis, the package
provides a forest plot of study-specific CACE estimates with 95% credible intervals
as well as the overall CACE estimate, to visually display the causal treatment effect
comparisons.
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This chapter is organized as follows. The next section defines CACE in mathemat-
ical notation that will be used throughout the paper. We also describe the assump-
tions needed to make the CACE a valid causal effect estimator. Section 4.2 presents an
overview of the Bayesian hierarchical models for CACE implemented in the BayesCACE
package. Section 4.3 illustrates use of the package with a case study example and dis-
cusses the output structures. Finally, Section 4.4 gives a short discussion with potential
future improvements.
4.1 CACE, assumptions and definition
The CACE is a measure of the causal effect of a treatment or intervention on patients
who received it as intended by the original group allocation. It is an unbiased causal
effect estimate based on five standard assumptions commonly used in causal inference
research. First, it assumes that potential outcomes for each participant are independent
of the potential outcomes for other participants, known as the Stable Unit Treatment
Value Assumption (SUTVA). Second, it assumes that assignment to treatment is ran-
dom, so that the proportion of compliers should be the same in the intervention and
control groups, thus allowing us to estimate one of the core unobserved parameters
needed to derive a CACE estimate. Third, it assumes that treatment assignment has
an effect on the outcome only if it changes the actual treatment taken, an assumption
known as the exclusion restriction. For never-takers, for instance, it assumes that sim-
ply being assigned to treatment does not affect their outcomes, as they do not actually
receive the treatment assignd to them. Fourth, it assumes that assigning the study
treatment to participants in the intervention condition induces at least some partici-
pants to receive the treatment, so the compliance rate is not zero. Finally, it assumes
there is a monotonic relationship between treatment assignment and treatment receipt,
which implies there are no individuals for whom assignment to treatment actually re-
duces the likelihood of receiving treatment (i.e., no defiers). This assumption reduces
the number of compliance types for whom estimates are derived, permitting a properly
identified model.
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We follow Zhou et al. (2019) and introduce notation both on the individual level and
on the study level. Suppose a meta-analysis reviews I two-armed randomized trials, Ni
is the number of subjects in the i-th trial, and i ∈ {1, . . . , I}. If the data include a single
study only, then I = 1 and we can remove the subscript i from all notation.
On the individual level, define notation as follows for subject j in trial i. (1) Let
Rij = r index the randomization assignment with r = 0 for those randomized to control
and r = 1 for those randomized to the intervention. (2) Let T rij = t ∈ {0, 1} be the
indicator of whether the individual received the intervention. This is a potential outcome
under the randomization assignment r ∈ {0, 1}, i.e., what the value of t would be for
individual (i, j) if r = 0 or r = 1, respectively. (3) Let Y r,tij = o ∈ {0, 1} be the potential
binary outcome under randomization assignment r and treatment received t. Note that
the exclusion restriction assumption allows us to define Y tij ≡ Y
r,t
ij . (4) The sets of
{Y r,tij } and {T rij} are the potential outcome and treatment-received status respectively
under possible r and t, but for each subject in a trial, only one of the possible values
of each set can be observed. Therefore, we denote the observed response and received
treatment variables as Yij and Tij . (5) We allow Tij = ∗ if the actual received treatment
is not recorded. Then let Mij = m be the missing indicator corresponding to whether
subject j has actual treatment received status on record (m = 0) or missing (m = 1).
(6) Using these potential outcomes, we can define the compliers and the CACE. Let Cij
be the latent compliance class of individual j in trial i, defined as follows:
Cij =

0, never-taker, if (T 0ij , T
1
ij) = (0, 0)
1, complier, if (T 0ij , T
1
ij) = (0, 1)
2, always-taker, if (T 0ij , T
1
ij) = (1, 1)
3, defier, if (T 0ij , T
1
ij) = (1, 0).
A subject’s compliance status Cij is not observable because in a two-arm trial, only
one of T 1ij and T
0
ij can be observed. Based on the observed randomization group and
actual treatment received, the compliance classes can be only partially identified.
Now, the complier average causal effect of the ith trial is the average difference
between potential outcomes for compliers. In this case, the CACE in study i is θCACEi =
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E(Y 1ij − Y 0ij |Cij = 1), where the patients for whom Cij = 1 are the compliers.
On the study level, Nirto denotes the observed number of individuals in study i,
randomization group r, actual received treatment group t, and outcome o. If the com-
pliance status of individual (i, j) is not on record, Tij = t = ∗ so the corresponding
count is Nir∗o, which is the sum of the two unobserved counts Nir0o and Nir1o.
4.2 Estimating CACE
In this section, the Bayesian hierarchical models used to estimate CACE are briefly
described. These models form the basis of the framework proposed by Zhou et al.
(2019) and underlie the BayesCACE package. Besides the notation defined in Section
4.1, define the following parameters for study i. (1) Let πia and πin be the probabilities
of being an always-taker and a never-taker, respectively. Because defiers are ruled
out by the monotonicity assumption introduced in Section 4.1, each trial has at most
only three compliance classes. Thus the probability of being a complier in study i is
πic = 1−πia−πin. (2) Define these response probabilities: ui1 for a complier randomized
to the treatment group; vi1 for a complier randomized to the control/placebo group; si1
for a never-taker; and bi1 for an always-taker. Thus for study i, the parameters included
in the model are βi = (πia, πin, ui1, vi1, si1, bi1). As the outcome is binary, the expected
difference between outcomes from the two treatment groups among compliers is just the
risk difference between ui1 and vi1. Therefore, the CACE defined in Section 4.1 can be
written as θCACEi = E(Y
1
ij − Y 0ij |Cij = 1) = ui1 − vi1.
4.2.1 CACE for a single trial with noncompliance
Consider first a single trial with noncompliance, i.e., I = 1, so all notation and pa-
rameters defined earlier are reduced to the version without subscript i. According to
Zhou et al. (2019), each observed Nrto has a corresponding probability that can be
written in terms of parameters defined earlier (see Table 4.1), where λ is the proportion
of assigning the active treatment (P(Rj = 1)), which is usually known in randomized
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trials. Thus the vector (N000, N001, N010, N011, N100, N101, N110, N111) follows a multi-
nomial distribution with parameters N and p, where N =
∑
Nrto and the elements of
p are listed in Table 4.1.
Table 4.1: Observed data and probabilities of a
single study
Observed Probabilities
N000 (1− λ){πc(1− v1) + πn(1− s1)}
N001 (1− λ)(πcv1 + πns1)




N110 λ{πc(1− u1) + πa(1− b1)}
N111 λ(πcu1 + πab1)
Therefore, the log likelihood is
logL(β) = N000log{πc(1− v1) + πn(1− s1)}+N001 log(πcv1 + πns1)}+
N010log{πa(1− b1) +N011log{πab1}+N100log{πn(1− s1)}+
N101log{πns1}+N110log{(πc(1− u1) + πa(1− b1)}+N111 log(πcu1 + πab1) (4.1)
Assigning a vague prior distribution f(β) to the parameters β = (πa, πn, u1, v1,
s1, b1), by Bayes’ theorem the joint posterior distribution is proportional to L(β)f(β).
Functionals of the posterior distribution can be estimated by Gibbs and Metropolis-
Hastings sampling algorithms using the software JAGS via the rjags package in R. The
CACE for a single study is u1− v1, so the posterior of θCACE is the posterior of u1− v1.
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4.2.2 CACE for a meta-analysis with complete compliance informa-
tion
This section introduces two methods for doing a meta-analysis of the CACE when
noncompliance data are reported in each trial.
The two-step approach
As described in Section 4.2.1, using the observed data Nirto, θ
CACE
i is identified for study
i. Therefore, to estimate the population-average CACE in a meta-analysis, intuitively
we can combine the study-specific estimates and standard errors using a standard meta-
analysis method such as the fixed-effect (Laird and Mosteller, 1990) or random effects
model (Hedges and Vevea, 1998; Hedges and Olkin, 2014). We call this a ”two-step”
approach. As the CACE measure is a risk difference, a transformation may be necessary
to ensure that the normal distribution assumption is approximately true. Building upon
the well-developed R package metafor, various estimators suggested in the literature can
be estimated to account for potential between-study heterogeneity in the CACE, e.g.,
the Hunter-Schmidt estimator, the Hedges estimator, the DerSimonian-Laird estimator,
the maximum-likelihood or restricted maximum-likelihood estimator, or the empirical
Bayes estimator (Viechtbauer, 2010).
The Bayesian hierarchical model
In a meta-analysis, the CACE can also be estimate using the joint likelihood from the
Bayesian hierarchical model. This method is systematically introduced in Zhou et al.
(2019). The log likelihood contribution of trial i is given by Equation 4.1 by adding a
subscript i to each parameter. Then the log likelihood for all trials in the meta-analysis is
logL(β) =
∑
i logLi(βi). Because the studies are probably not exactly identical in their
eligibility criteria, measurement techniques, study quality, etc., differences in methods
and sample characteristics may introduce heterogeneity to the meta-analysis. One way
to model the heterogeneity is to use a random effects model.
To guarantee the desired properties of study i’s latent compliance classes and to
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account for possible between-study heterogeneity in the compliance class and response







, where ni = αn+ δin, ai = αa+ δia,
and (δin, δia)





(2) g(si1) = αs + δis, g(bi1) = αb + δib, g(ui1) = αu + δiu, g(vi1) = αv + δiv,
where g(·) is a link function such as the logit or probit, δis ∼ N(0, σ2s), δib ∼ N(0, σ2b ),
δiu ∼ N(0, σ2u), δiv ∼ N(0, σ2v).
Here we allow correlation between ni and ai, and assign random effect variables to
all parameters. However, if a parameter does not very between trials, it can be modeled
as a fixed effect. Let f(βi|β0,Σ0) be the distributions described above of all parameters
βi = (πia, πin, si1, bi1, ui1, vi1), where β0 is the vector of mean hyper-parameters (αn,







v . If we specify f(β0) and f(Σ0) as the prior distributions for the hyper-




As stated at the beginning of Section 4.2, θCACEi = ui1 − vi1 for study i, so for the
meta-analysis, the overall CACE is θCACE = E(θCACEi ) = E(ui1) − E(vi1). When a
random effect δiu or δiv is not assigned in the model, E(ui1) = g
−1(αu) and E(vi1) =
g−1(αv). Otherwise, E(ui1) and E(vi1) can be estimated by integrating out the random








)dt, where φ(·) is the standard Gaussian




). If the link function g(·) is logit, a well-established approximation
E(ui1) ≈ logit−1( αu√
1+C2σ2u
) can be used, where C = 16
√
3
15π (Zeger et al., 1988). The
above formulas also apply to E(vi1), the expected response rate of a complier in the
control group.
The two-step approach, stated by Lin and Zeng (2010), can be viewed as asymp-
totically equivalent to the model using the joint likelihood. However, as the two-step
approach requires the whole set of parameters to be estimated independently for each
study, the total number of effective parameters tends to be larger than this method, so
estimates using the Bayesian hierarchical model are likely to be more efficient.
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4.2.3 CACE for meta-analysis with incomplete compliance informa-
tion
Another advantage of the Bayesian hierarchical model is that it can include trials with
incomplete compliance data. Commonly, some trials do not report noncompliance data
because study investigators do not collect actual received treatment status for some
subjects or simply do not report compliance. The two-step approach needs counts for
all of the groups defined by randomized assignment, treatment received, and outcome in
order to estimate the study specific θCACEi , so using this method, trials with incomplete
compliance data are simply excluded, making estimation less efficient and potentially
biased.
In Chapter 3 we proposed a comprehensive framework to incorporate both heteroge-
neous and incomplete noncompliance data for estimating the CACE in a meta-analysis
of RCTs. Here we present the data structure needed for binary outcomes. Table 4.2
shows the probabilities corresponding to the observed counts data. For study i, random-
ization group r ∈ {0, 1}, if the compliance information is reported, then values of Nir0o
and Nir1o are reported, where o ∈ {0, 1}, so we assign the marginal count Nir∗o = 0.
Otherwise, we do not have data on outcomes for groups defined by actually received
treatment, so only the marginal Nir∗o is observed, where Nir∗o is the number of patients
randomized to treatment arm r who had outcome o, for r, o ∈ {0, 1}. In this situation,
the two unobserved counts Nir0o and Nir1o are assigned as 0.
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Table 4.2: Observed data and probabilities in study i of a meta-
analysis with incomplete compliance
Observed Probabilities
Ni000 (1− λi){πic(1− vi1) + πin(1− si1)}
Ni001 (1− λi)(πicvi1 + πinsi1)




Ni110 λi{(πic(1− ui1) + πia(1− bi1)}
Ni111 λi(πicui1 + πiabi1)
Ni0∗0 (1− λi){πic(1− vi1) + πin(1− si1) + πia(1− bi1)}
Ni0∗1 (1− λi)(πicvi1 + πinsi1 + πiabi1)
Ni1∗0 λi{(πic(1− ui1) + πia(1− bi1) + πin(1− si1)}
Ni1∗1 λi(πicui1 + πiabi1 + πinsi1)
After organizing the observed data as above, Table 4.2 shows the relation between
each observed count and the corresponding probability, which is a function of the pa-
rameters defined in Section 4.2.2. As before, λi is the known allocation ratio for study
i, i.e, λi = P(Rij = 1).
The log likelihood contribution for trial i is obtained from the multinomial distribu-
tion:
logLi(βi) = Ni000log{πic(1− vi1) + πin(1− si1)}+Ni001 log(πicvi1 + πinsi1)+
Ni010log{πiia(1− bi1)}+Ni011log{πiabi1}+Ni100log{πin(1− si1)}+
Ni101log{πinsi1}+Ni110log{(πic(1− ui1) + πia(1− bi1)}+Ni111 log(πicui1 + πiabi1)+
Ni0∗0log{πic(1− vi1) + πin(1− si1) + πia(1− bi1)}+Ni0∗1 log(πicvi1 + πinsi1 + πiabi1)+
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Ni1∗0log{(πic(1− ui1) + πia(1− bi1) + πin(1− si1)}+Ni1∗1 log(πicui1 + πiabi1 + πinsi1)
(4.2)
Because the parameters βi = (πia, πin, si1, bi1, ui1, vi1) are the same as in Sec-
tion 4.2.2, the estimation process is also the same: assign distributions f(βi|β0,Σ0),
where β0 is the vector of mean hyper-parameters, and Σ0 is the covariance matrix; then
specify prior distributions for f(β0) and f(Σ0), so the joint posterior is proportional
to
∏
i Li(βi)f(βi|β0,Σ0)f(β0)f(Σ0). Similarly, the CACE for this meta-analysis in-





) if the probit link function is used for ui1 and vi1.
4.3 Using the R package BayesCACE
The primary objective of the BayesCACE package is to provide a user-friendly im-
plementation of the Bayesian method for estimating the CACE, described in Section
4.2. The package is now available to download and install from GitHub at https:
//github.com/JinchengZ/BayesCACE. It will soon be available via the Comprehensive
R Archive Network (CRAN) at https://CRAN.R-project.org/package=BayesCACE.
The BayesCACE package depends on the R packages rjags (Plummer, 2018), coda
(Plummer et al., 2006), and forestplot (Gordon and Lumley, 2017). Users need to in-
stall JAGS separately from its homepage http://mcmc-jags.sourceforge.net as the
BayesCACE package does not include a copy of the JAGS library. The current version
of JAGS is 4.3.0, which is the version of the package BayesCACE requires; earlier ver-
sions of JAGS may not guarantee exactly reproducible results. Once the package has
been correctly installed, it should be possible to replicate the analyses described in this
section to within MCMC error.
4.3.1 Data structure for estimating the CACE
We introduce the data structures through the illustration example included in the pack-
age BayesCACE: epidural_c and epidural_ic. These two data sets were obtained
from Bannister-Tyrrell et al. (2015), who conducted an exploratory meta-analysis of
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the association between using epidural analgesia in labor and the risk of cesarean sec-
tion. Data epidural_c contains 10 trials with full compliance information; each trial
has 8 observed counts, denoted by Nirto and presented in columns Nirto, i = 1, . . . , 10,
r, t, o ∈ {0, 1}. These data were re-analyzed by Zhou et al. (2019) in a meta-analysis
using their proposed Bayesian hierarchical model to estimate the CACE. The func-
tion cace.meta.c() introduced in Section 4.3.3 performs this analysis. The column
study.id contains IDs for the 10 studies, and study.name labels each study by its first
author’s surname and its publication year.
The data can be loaded and printed using these commands:
R> library("BayesCACE")
R> data("epidural_c", package = "BayesCACE")
R> epidural_c
study.id study.name N000 N001 N010 N011 N100 N101 N110 N111
1 1 Bofill, 1997 37 2 11 1 2 0 42 5
2 2 Clark, 1998 72 6 68 16 7 2 134 13
3 3 Halpern, 2004 62 5 44 7 0 0 112 12
4 4 Head, 2002 51 7 2 0 3 0 43 10
5 5 Jain, 2003 72 11 0 0 0 2 36 7
6 6 Nafisi, 2006 179 19 0 0 0 0 173 24
7 7 Nikkola, 1997 6 0 4 0 0 0 10 0
8 8 Ramin, 1995 546 17 95 8 230 2 393 39
9 9 Sharma, 1997 336 16 5 0 114 1 231 12
10 10 Volmanen, 2008 23 1 3 0 1 0 23 1
The other dataset epidural_ic represents the situation in which not all trials re-
port complete compliance data. It contains 27 studies, only 10 out of which have full
compliance information and were included in epidural_c. This dataset is also drawn
from Bannister-Tyrrell et al. (2015) but only the method introduced in Section 4.2.3 can
include the studies with incomplete compliance information when estimating the CACE.
The function cace.meta.ic() (see Section 4.3.3 for details) performs this analysis.
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Each study is represented by one row in the dataset; the columns study.id and
study.name have the same meanings as in the dataset epidural_c. Each study’s data
is summarized in 12 numbers (columns) denoted by Nirto and Nir∗o as described in
Section 4.2.3. For a particular randomization group r ∈ {0, 1}, observed counts are
presented either as Nirto or Nir∗o depending on whether the compliance information is
available; values for other columns are denoted by 0. The corresponding column names
in the dataset are Nirto and Nirso, respectively.
The first 6 rows of the dataset epidural_ic are printed below.
R> data("epidural_ic", package = "BayesCACE")
R> head(epidural_ic)
study.id study.name N000 N001 N010 N011 N0s0 N0s1 N100 N101 N110 N111 N1s0 N1s1
1 1 Bofill, 1997 37 2 11 1 0 0 2 0 42 5 0 0
2 2 Clark, 1998 72 6 68 16 0 0 7 2 134 13 0 0
3 3 Dickinson, 2002 0 0 0 0 428 71 0 0 0 0 408 85
4 4 Evron, 2008 40 4 0 0 0 0 0 0 0 0 129 19
5 5 El Kerdawy, 2010 0 0 0 0 12 3 0 0 0 0 11 4
6 6 Gambling, 1998 0 0 0 0 573 34 206 10 371 29 0 0
Note that NA is not allowed in a dataset for the package BayesCACE, but some trials
may have 0 events or 0 noncompliance rates.
4.3.2 Plotting noncompliance rates
Before doing the CACE analysis, one might want a visual overview of the study-specific
noncompliance rates in both randomization arms. The function plot.noncomp provides
a forest plot of noncompliance rates in an R plot window. The function can be simply
called as
plot.noncomp(data, overall=TRUE),
where data is a dataset with structure like epidural_c or epidural_ic. Only
studies with full compliance information are included in this plot because noncompliance
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rates cannot be calculated without compliance data. Figure 4.1 shows the resulting plot,
where the red dot with its horizontal line shows the study-specific noncompliance rate
with its 95% exact confidence interval for the patients randomized to the treatment arm,
and the blue square with its horizontal line represents that rate and interval for those in
the control arm. The confidence intervals are calculated by the Clopper-Pearson exact
method (Clopper and Pearson, 1934), which is based on the cumulative distribution
function of the binomial distribution. By default overall=TRUE so that the figure also
gives a summary estimate of the compliance rates per randomization group. This overall
rate is estimated using a logit generalized linear mixed model. Otherwise if the argument





































0 0.2 0.4 0.6
Nocompliance Rates
P(T=0|R=1) P(T=1|R=0)
Figure 4.1: Noncompliance rates plot generated by the function plot.noncomp().
4.3.3 CACE analysis for a single study or in a meta-analysis
The major functions in the BayesCACE package are cace.study(), cace.meta.c(),
and cace.meta.ic(), which implement the models introduced in Section 4.2 to perform
Bayesian CACE analysis for different data structures. In particular, cace.study() does
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CACE analysis for a single study using the likelihood and model specified in Section
4.2.1. The function cace.meta.c() does CACE analysis for a meta-analysis when
each trial reports noncompliance information. Users can choose to do the analysis ei-
ther by the two-step approach or using the Bayesian hierarchical model, as introduced
in Section 4.2.2. When some trials do not report noncompliance data, the function
cace.meta.ic() can be applied to perform a CACE meta-analysis using the likelihood
in Equation 4.2. The commands in each function may take 1-15 minutes to run. Gen-
erally the two-step approach using the function cace.meta.c() takes longer because
MCMC chains are run on the studies one by one. The actual run time depends on the
amount of data and the user’s processor.
Function cace.study() for a study-specific analysis or a two-step meta-analysis
For the default interface, the arguments of the function cace.study() are
cace.study(data, param = c("CACE", "u1", "v1", "s1", "b1", "pi.c", "pi.n",
"pi.a"), prior.type = "default", digits = 3, n.adapt = 1000, n.iter =
100000, n.burnin = floor(n.iter/2), n.chains = 3, n.thin = max(1, floor
((n.iter - n.burnin)/1e+05)), conv.diag = FALSE, mcmc.samples = FALSE,
two.step = FALSE, method = "REML")
where users need to input data with the same structure as epidural_c, containing
either one row of observations for a single study, or multiple rows referring to multiple
studies in a meta-analysis. This function fits a model for a single study as described in
Section 4.2.1. If the data includes more than one study, the study-specific CACEs will
be estimated by retrieving data row by row.
The argument param is a character string vector indicating the parameters to be
tracked and estimated. By default all parameters shown in Section 4.2.1 are included:
θCACE (CACE), u1 (u1), v1 (v1), s1 (s1), b1 (b1), πa (pi.a), πn (pi.n), and πc = 1−πa−πn
(pi.c). Users can modify the string vector to only include parameters of interest be-
sides θCACE. If users do not specify their own prior distributions, the default pri-
ors are used (prior.type = "default"). They are assigned to the transformed scale
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of the following parameters: πn =
exp(n)
1+exp(n)+exp(a) , πa =
exp(a)
1+exp(n)+exp(a) , logit(s1) =
αs, logit(b1) = αb, probit(u1) = αu, probit(v1) = αv, where n, a ∼ N(0, 2.52) and
αs, αb, αu, αv ∼ N(0, 22). With these settings, a 95% prior probability interval for any
of the probabilities πin, πia, and πic ranges from about 0.001 to 0.91, and a 95% prior
interval for the probabilities s1, b1, u1, and v1 ranges from about 0.01 to 0.98. Alter-
natively, users can specify their own prior distributions for all parameters, and save
them as a file prior.study.R under the same directory with the model function. By
assigning prior.type = "custom", the function calls the user-defined text string as the
priors. Note that if users choose the customized priors, the pre-defined prior.study.R
must include distributions for all parameters. The function cannot combine the de-
fault priors with partial user-defined prior distributions. Here we give an example of




n ~ dnorm(0, 0.01)
a ~ dnorm(0, 0.01)
alpha.s ~ dnorm(0, 0.01)
alpha.b ~ dnorm(0, 0.01)
alpha.u ~ dnorm(0, 0.01)




The arguments n.adapt, n.iter, n.burnin, n.chains, and n.thin control the
MCMC algorithm run by the R package rjags (Plummer, 2018). The argument n.adapt
is the number of iterations for adaptation; it is used to maximize the sampling effi-
ciency, and the default is set as 1,000. The argument n.chains determines the number
of MCMC chains (the default is 3); n.iter is the number of iterations of each MCMC
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chain; n.burnin is the number of burn-in iterations at the beginning of each chain to
be discarded; n.thin is the thinning rate for MCMC chains, which is used to avoid
potential high auto-correlation and to save computer memory when n.iter is large.
The default of n.thin is set as 1 or the largest integer not greater than ((n.iter-
n.burnin)/1e+05)), whichever is larger. The argument conv.diag specifies whether
to compute the Gelman and Rubin convergence statistic (R̂) of each parameter as a
convergence diagnostic (Brooks and Gelman, 1998; Gelman and Rubin, 1992). It is
considered the chains are well mixed and have converged to the target distribution if
R̂ ≤ 1.1. If the argument mcmc.samples = TRUE, the function saves each chain’s MCMC
samples for all parameters, which can be used to produce trace, posterior density, and
auto-correlation plots by calling the function plot.cacebayes.
By default, the function cace.study() returns a list including posterior estimates
(posterior mean, standard deviation, median, and a 95% credible interval (CI) with
2.5% and 97.5% quantiles as the lower and upper bounds), and the deviance informa-
tion criterion (DIC) statistic (Spiegelhalter et al., 2002) for each study. The argument
two.step is a logical value indicating whether to conduct a two-step meta-analysis. If
two.step = TRUE, the posterior mean and standard deviation of study-specific θCACEi
are used to do a standard meta-analysis, using the R package metafor. The default esti-
mation method is the REML (restricted maximum-likelihood estimator) method for the
random-effects model (Harville, 1977). Users can change the argument method to obtain
different meta-analysis estimators from either a random-effects model or a fixed-effect
model, e.g., method = "DL" refers to the DerSimonian-Laird estimator, method = "HE"
returns the Hedges estimator, and method = "HS" gives the Hunter-Schmidt estima-
tor. More details are available from the documentation of the function metafor::rma
(Viechtbauer, 2010). If the input data include only one study, the meta-analysis result
is just the same as the result from the single study.
Here is an example to demonstrate the function’s usage. We call the function
cace.study() on the dataset epidural_c as follows:
R> data("epidural_c", package = "BayesCACE")
R> set.seed(123)
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R> out.study <- cace.study(data = epidural_c, conv.diag = TRUE, mcmc.samples
+ = TRUE, two.step = TRUE)
The following messages are output as the code runs:
NA is not allowed in the input data set;





Observed stochastic nodes: 2
Unobserved stochastic nodes: 6





MCMC convergence diagnostic statistics are calculated and saved in conv.out
If the dataset contains more than one study, e.g., the epidural_c dataset has 10
trials, then once the JAGS model compiles for the first study, it automatically continues
to run on the next study’s data. The results are saved in the object out.study, a list
containing the model name, posterior information for each monitored parameter, and
DIC of each study. We can use parameter names to display the corresponding estimates.
The argument digits in the function cace.study() can be used to change the number
of significant digits to the right of the decimal point. Here, we used the default setting
digits = 3. For example, the estimates of θCACE for each single study (posterior
mean and standard deviation, posterior median, 95% credible interval, and time-series
standard error) can be displayed as
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R> out.study$CACE
Mean SD 2.5% 50% 97.5% Time-series SE
[1,] 0.04960 0.0796 -0.0944 4.41e-02 0.2180 2.52e-04
[2,] -0.02460 0.0488 -0.1220 -2.19e-02 0.0789 1.48e-04
[3,] -0.02180 0.0609 -0.1270 -2.88e-02 0.1130 1.93e-04
[4,] 0.07180 0.0762 -0.0769 7.12e-02 0.2240 2.05e-04
[5,] 0.08260 0.0765 -0.0620 8.13e-02 0.2370 2.52e-04
[6,] 0.02600 0.0318 -0.0362 2.58e-02 0.0887 7.42e-05
[7,] 0.01420 0.1560 -0.2770 2.11e-04 0.4000 4.07e-04
[8,] 0.05020 0.0247 0.0024 5.00e-02 0.0992 7.26e-05
[9,] -0.01090 0.0234 -0.0571 -1.08e-02 0.0349 6.29e-05
[10,] 0.00127 0.0649 -0.1340 -3.87e-06 0.1430 1.53e-04
If the argument conv.diag is specified as TRUE, the output list contains a sub-list
conv.out, which outputs the point estimates of the ‘potential scale reduction factor’
(the Gelman and Rubin convergence statistic, labelled Point est.) calculated for each
parameter from each single study, and their upper confidence limits (labelled Upper
C.I.). Approximate convergence is diagnosed when the upper limit is close to 1 (Brooks
and Gelman, 1998; Gelman and Rubin, 1992). For example, the first sub-list from
conv.out is
R> out.study$conv.out[[1]]










Also, in this example, we included mcmc.samples = TRUE in the argument, so the output
object list out.study includes each chain’s MCMC samples for all parameters. They
can be used in the function plot.cacebayes to generate the trace, posterior density,
and auto-correlation plots for further model diagnostics.
If the dataset used by the function cace.study() has more than one study, spec-
ifying the argument two.step = TRUE causes the two-step meta-analysis for θCACE to
be done. The outcomes are saved as a sub-list object meta. Note that users can ob-
tain different meta-analysis estimators by changing the method argument as described
earlier.
R> out.study$meta
Random-Effects Model (k = 10; tau^2 estimator: REML)
tau^2 (estimated amount of total heterogeneity): 0.0002 (SE = 0.0008)
tau (square root of estimated tau^2 value): 0.0129
I^2 (total heterogeneity / total variability): 8.00%
H^2 (total variability / sampling variability): 1.09
Test for Heterogeneity:
Q(df = 9) = 5.9134, p-val = 0.7486
Model Results:
estimate se zval pval ci.lb ci.ub
0.0183 0.0142 1.2854 0.1986 -0.0096 0.0462
---
Signif. codes: 0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1
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Function cace.meta.c() for meta-analysis with complete compliance data
The function cace.meta.c() performs the Bayesian hierarchical model method for
meta-analysis when the dataset has complete compliance information for all studies,
as described in Section 4.2.2. The function’s default arguments are given by
cace.meta.c(data, param = c("CACE", "u1out", "v1out", "s1out", "b1out",
"pic", "pin", "pia"), prior.type = "default", delta.n = TRUE, delta.a
= TRUE, delta.u = TRUE, delta.v = TRUE, delta.s = TRUE, delta.b = TRUE,
cor = TRUE, digits = 3, n.adapt = 1000, n.iter = 100000, n.burnin =
floor(n.iter/2), n.chains = 3, n.thin = max(1, floor((n.iter - n.burnin)
/100000)), conv.diag = FALSE, mcmc.samples = FALSE,
study.specific = FALSE)
The arguments controlling the MCMC algorithm are mostly similar to those of cace.
study(). One major difference is that users need to specify parameters that are modeled
as random effects. In Section 4.2.2, we showed how to specify random effects for each
parameter on the transformed scales, namely δin, δia, δiu, δiv, δis, and δib, and allowed
a non-zero correlation ρ between δin and δia. The model with all of these random
effects as well as the correlation ρ is considered the full model. However, this function
is flexible, allowing users to choose which random effects to include by specifying the
logical-valued arguments delta.n, delta.a, delta.u, delta.v, delta.s, delta.b, and
cor, respectively. The default model sets all of these arguments to TRUE. Note that ρ
(cor) can only be included when both δin (delta.n) and δia (delta.a) are set to TRUE.
Otherwise, a warning occurs and the model continues running by forcing delta.n =
TRUE and delta.a = TRUE. The default parameters to be monitored depend on which
parameters are modeled as random effects. For example, u1out refers to E(ui1) as
described in Section 4.2.2, where for the probit link, E(ui1) = Φ(αu) if δu is not specified
in the model, and E(ui1) = Φ(
αu√
1+σ2u
) when the random effect δu is included.
The argument prior.type = "default" is used if users do not specify prior distri-
butions. Like the function cace.study, weakly informative priors αn, αa ∼ N(0, 2.52)
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, where ni = αn + δin, ai = αa + δia;
logit(si1) = αs + δis, logit(bi1) = αb + δib, probit(ui1) = αu + δiu, and probit(vi1) =
αv + δiv. For the random effects, we have δis ∼ N(0, σ2s), δib ∼ N(0, σ2b ), δiu ∼ N(0, σ2u),
and δiv ∼ N(0, σ2v), as response rates are assumed to be independent between latent







v , which corresponds to a 95% interval of (0.6, 2.9) for the cor-
responding standard deviations, allowing moderate heterogeneity in the response rates.
In a reduced model with one of δin or δia set to 0, the prior of the other precision param-
eter is also assumed to be Gamma(2, 2), which gives moderate heterogeneity for latent
compliance classes probabilities, whereas for the full model, (δin, δia)
T ∼ N(0, Σps),
the prior for the variance-covariance matrix Σps is InvWishart(I, 3), where I is the
identity matrix.
Alternatively, this function allows users to specify their own prior distributions by
saving a separate R file prior.meta.R under the save directory with the model file, and
assigning the argument prior.type = "custom". Because the function cace.meta.c()
is more complicated depending on the choice of random effects, as an illustration we
show an example of the customized prior distributions file when assigning delta.n =
TRUE, delta.a = FALSE, delta.u = TRUE, delta.v = FALSE, delta.s = TRUE, cor =
FALSE to function cace.meta.c().
prior.meta <- function(prior.type="custom"){
string2 <-
" delta.n[i] ~ dnorm(0, tau.n)
delta.u[i] ~ dnorm(0, tau.u)




alpha.n ~ dnorm(0, 0.16)
alpha.a ~ dnorm(0, 0.16)
alpha.s ~ dnorm(0, 0.25)
alpha.b ~ dnorm(0, 0.25)
alpha.u ~ dnorm(0, 0.25)
alpha.v ~ dnorm(0, 0.25)
tau.n ~ dgamma(2, 2)
sigma.n <- 1/sqrt(tau.n)





s1out <- ilogit(alpha.s/sqrt(1 + (16^2*3/(15^2*pi^2))*sigma.s^2))






Users can modify the above customized file prior.meta.R to assign their preferred
prior distributions. Note that same as the function cace.study(), the function cannot
combine the default priors with partial user-defined prior distributions. Thus users need
to be careful when choosing the customized priors: the pre-defined R file prior.meta.R
must include distributions for all hyper-parameters.
The epidural_c dataset is used as a real-study example:
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R> data("epidural_c", package = "BayesCACE")
R> set.seed(123)
R> out.meta.c <- cace.meta.c(data = epidural_c, conv.diag = TRUE,
+ mcmc.samples = TRUE, study.specific = TRUE)
The usage of arguments conv.diag and mcmc.samples are the same as for the function
cace.study. When the argument study.specific is specified as TRUE, the model will
first check the logical status of arguments delta.u and delta.v. If both are FALSE,
meaning that neither response rate ui1 or vi1 is modeled with a random effect, then
the study-specific θCACEi is the same across studies. The function gives a warning and
continues by making study.specific = FALSE. Otherwise, the study-specific θCACEi
are estimated and saved as the parameter cacei.
In this example, by calling the object smry from the output list out.meta.c, poste-
rior estimates (posterior estimates (posterior mean, standard deviation, posterior me-
dian, 95% credible interval, and time-series standard error) are displayed.
R> out.meta.c$smry
Mean SD 2.5% 50% 97.5% Time-series SE
CACE 0.020900 0.0632 -0.10200 1.94e-02 0.1510 7.72e-04
b1out 0.127000 0.0451 0.05930 1.20e-01 0.2340 3.91e-04
cacei[1] 0.044000 0.0678 -0.08140 4.08e-02 0.1870 2.32e-04
cacei[2] -0.023100 0.0491 -0.11500 -2.50e-02 0.0820 1.84e-04
cacei[3] -0.007330 0.0566 -0.10900 -1.14e-02 0.1130 2.13e-04
cacei[4] 0.065400 0.0680 -0.06650 6.46e-02 0.2020 1.66e-04
cacei[5] 0.053800 0.0685 -0.07310 5.11e-02 0.1950 2.42e-04
cacei[6] 0.026300 0.0308 -0.03390 2.61e-02 0.0872 6.78e-05
cacei[7] 0.003040 0.0933 -0.18900 6.39e-05 0.2100 3.56e-04
cacei[8] 0.048400 0.0237 0.00215 4.83e-02 0.0953 6.25e-05
cacei[9] -0.010700 0.0224 -0.05530 -1.06e-02 0.0331 5.58e-05
cacei[10] 0.000278 0.0604 -0.12100 -1.29e-03 0.1290 2.08e-04
pia 0.121000 0.0804 0.02550 1.02e-01 0.3450 4.69e-03
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pic 0.815000 0.0948 0.55900 8.34e-01 0.9330 5.84e-03
pin 0.064500 0.0401 0.01540 5.59e-02 0.1590 2.32e-03
s1out 0.183000 0.1040 0.04540 1.60e-01 0.4400 8.93e-04
u1out 0.128000 0.0480 0.05540 1.20e-01 0.2430 6.14e-04
v1out 0.107000 0.0406 0.04740 1.00e-01 0.2040 4.61e-04
The posterior estimates of θCACEi can be used to make a forest plot by calling the
function plot.forest, which will be introduced in Section 4.3.5.
Users can manually do model selection procedures by including different random
effects and comparing DIC from the outputs. DIC and its two components are saved as





DIC is the penalized deviance, calculated as the sum of D.bar and pD, where D.bar is the
posterior expectation of the deviance, reflecting the model fit, and pD reflects the effective
number of parameters in the model. D.bar is usually lower when more parameters are
included in the model, but complex models may lead to overfitting. Thus DIC balances
the model’s fit against the effective number of parameters. Generally a model with
smaller DIC is preferred. However, it is difficult to say what constitutes an important
improvement in DIC. Following Lunn et al. (2012), we suggest that a reduction of less
than 5 is not a substantial improvement. When fitting models to a particular dataset, it
is usually uncertain which random effect variables should be included in the model. The
function cace.meta.c() allows users to specify candidate models with different random
effects, and thus to conduct a forward/backward/stepwise model selection procedure to
choose the best fitting model.
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Function cace.meta.ic() for meta-analysis with incomplete compliance in-
formation
Another major function in the package BayesCACE is cace.meta.ic(). It also esti-
mates θCACE using the Bayesian hierarchcal model but can accommodate studies with
incomplete compliance data. The necessary data structure and the likelihood function
are presented in Section 4.2.3. The arguments of this function are
cace.meta.ic(data, param = c("CACE", "u1out", "v1out", "s1out", "b1out",
"pic", "pin", "pia"), prior.type = "default", delta.n = TRUE, delta.a
= TRUE, delta.u = TRUE, delta.v = TRUE, delta.s = TRUE, delta.b =
TRUE, cor = TRUE, n.burnin = floor(n.iter/2), digits = 3, n.adapt =
1000, n.iter = 100000, n.chains = 3, n.thin = max(1, floor((n.iter -
n.burnin)/100000)), conv.diag = FALSE, mcmc.samples = FALSE,
study.specific = FALSE)
The arguments of cace.meta.ic() are mostly similar to those of cace.meta.c(),
though cace.meta.ic() calls a different built-in model file from the package BayesCACE.
The major difference in using this function is that users need to create a dataset with
the same structure as epidural_ic. Please check Section 4.3.1 for data preparation
details. As for cace.meta.c(), users can set their customized prior distributions by
saving them as a separate R file prior.meta.R. Here we use the epidural_ic dataset
as an example:
R> data("epidural_ic", package = "BayesCACE")
R> set.seed(123)
R> out.meta.ic <- cace.meta.ic(data = epidural_ic, conv.diag = TRUE,
+ mcmc.samples = TRUE, study.specific = TRUE)
The results are saved in the object out.meta.ic, a list containing posterior estimates
for monitored parameters, DIC, convergence diagnostic statistics, and MCMC sam-
ples. In this example, the argument study.specific is TRUE, so the summary for each
study-specific θCACEi is displayed in the object out.meta.ic$smry together with other
parameters.
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Note that when compiling the JAGS model, the warning ”adaptation incomplete”
may occasionally occur, indicating that the number of iterations for the adaptation
process is not sufficient. The default value of n.adapt (the number of iterations for
adaptation) is 1,000. This is an initial sampling phase during which the samplers adapt
their behavior to maximize their efficiency (e.g., a Metropolis-Hastings random walk
algorithm may change its step size) (Plummer, 2018). The ”adaptation incomplete”
warning indicates the MCMC algorithm may not achieve maximum efficiency, but it
generally has little impact on the posterior estimates of the treatment effects. To avoid
this warning, users may increase n.adapt.
4.3.4 Plotting the trace plot, posterior density, and auto-correlation
When compiling the JAGS models, it is helpful to assess the performance of the MCMC
algorithm. The function plot.cacebaes() provides diagnostic plots for the MCMC,
namely trace plots, auto-correlation plots and kernel density estimation plots. Both
trace plots and the auto-correlation plots can be used to examine whether the MCMC
chains appear to be drawn from stationary distributions. A posterior density plot for a
parameter visually shows the posterior distribution. Users can simply call this function
on objects produced by cace.study(), cace.meta.c(), or cace.meta.ic().
The arguments of this plot function are
plot.cacebayes(obj, which = c("trace", "density", "autocorr"), param =
c("CACE"), trialnumber = 1, ...)
Here, we use the objects list obtained from fitting the Bayesian hierarchical model
cace.meta.ic() in Section 4.3.3 as examples to generate the three plots. To avoid
lengthy output we just illustrate how these plots are produced for θCACE. The relevant
code is:
R> plot.cacebayes(obj = out.meta.ic)
The resulting plots are shown in Figure 4.2, 4.3, and 4.4.
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Figure 4.2: Trace plot for θCACE on the epidrual_ic dataset from the model
cace.meta.ic().
The trace plot, Figure 4.2, shows the parameter values sampled at each iteration
versus the iteration number. Each color represents one chain. Here we used the default
n.chains = 3. The trace plot shows evidence that the posterior samples of θCACE are
drawn from the stationary distribution.
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Figure 4.3: The kernel smoothed density for θCACE from the function cace.meta.ic()
applied to the epidural analgesia in labor meta-analysis.
The density plot, Figure 4.3, is smoothed using the R function density(). It shows
that the kernel-smoothed posterior of θCACE is almost symmetric. The posterior mean
is not far from 0, indicating that the complier average causal effect of using epidural
analgesia in labor on cesarean section is likely not significant.
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Figure 4.4: Auto-correlation plot of θCACE from the model cace.meta.ic() fit to the
epidrual_ic dataset.
The autocorrelation plot, Figure 4.4, is a bar plot displaying the auto-correlation for
different lags. At lag 0, the value of the chain has perfect auto-correlation with itself.
As the lag becomes greater, the values become less correlated. After a lag of about
50, the auto-correlation drops below 0.1. If the plot shows high auto-correlation, users
can run the chain longer or can choose a larger n.thin, e.g., n.thin=10 would keep
only 1 out of every 10 iterations, so that the thinned out chain is expected to have the
auto-correlation dropping quickly.
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4.3.5 Plotting the study-specific CACE in a forest plot
A graphical overview of the results can be obtained by creating a forest plot (Lewis and
Clarke, 2001). The function plot.forest() draws a forest plot for θCACE estimated
from the meta-analysis. Users can call this function for the objects from cace.meta.c()
or cace.meta.ic(). Here is an example using the object out.meta.ic:
R> plot.forest(data = epidural_ic, obj = out.meta.ic)
Note that in addition to the object out.meta.ic, users also need to specify the dataset
used to compute that object, from which the plot.forest() function extracts the study
names and publication years for the figure.
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Figure 4.5: Forest plot of study-specific θCACE from the model cace.meta.ic() with
full random effects fit to the epidural_ic dataset.
Figure 4.5 is a forest plot of θCACEi for each study individually, using the Bayesian
method with full random effects and default priors. The summary estimate based on
the model cace.meta.ic() is automatically added to the figure, with the outer edges of
the polygon indicating the confidence interval limits. The 95% credible interval of the
summary θCACE covers zero, indicating a non-significant complier average causal effect
estimate for using epidural analgesia in labor on the risk of cesarean section for the
meta-analysis with 27 trials. For a study with incomplete data on compliance status, a
dashed horizontal line in the forest plot is used to represent the posterior 95% credible




vary from negative to positive in individual studies, while most of the 95% credible
intervals cover zero. As the θCACEi for a trial without complete compliance data is not
estimable using only data from that single trial, dashed lines tend to have longer credible
intervals than those with complete data (solid lines).
If neither random effect δiu nor δiv is included in the model (delta.u = FALSE,
delta.v = FALSE in the calls to cace.meta.c() or cace.meta.ic()), the study-specific
θCACEi = ui1− vi1 are the same across trials, so a forest plot cannot be made. However,
the function cace.study() can estimate CACE separately for an individual trial as long
as it has complete compliance data. In that case, users can choose to generate a forest
plot θCACEi for each individual study based on separate analyses. The pooled estimate of
θCACE and its 95% credible interval or confidence interval (the diamond in the plot) can
be either from the Bayesian hierarchical model (the cace.meta.c() function) or from
the two-step approach cace.study() function with the argument two.step = TRUE).
The following code is an example of how to create such a plot:
R> plot.forest(data = epidural_c, obj = out.study, obj2 = out.meta.c)
If obj contains the two-step meta-analysis result, the argument obj2 is optional and is
included if the user wants to report the summary CACE estimate based on the Bayesian
hierarchical model cace.meta.ic().
4.4 Discussion
This chapter is meant to provide an overview of the BayesCACE package for conducting
CACE analysis with R. Bayesian hierarchical models estimating the CACE in individual
studies and in meta-analysis are introduced to demonstrate the underlying methods
of the functions. Practical usage of various functions is illustrated using real meta-
analyses datasets epidural_c and epidural_ic. The package provides several plots
for interpretation of model outputs and model diagnosis.
It is important to note that the two-step approach for meta-analysis is included in the
package BayesCACE because by using the full observed data from a single study i, θCACEi
92
is identifiable, making it possible to pool the estimated posterior means and standard
deviations of the θCACEi in a meta-analysis. However, the Bayesian hierarchical-model
meta-analysis method for estimating the overall CACE, introduced in Sections 4.2.2
and 4.2.3, is preferred for two reasons: the conventional two-step approach requires the
whole set of parameters to be estimated for each trial, giving a larger total number
of parameters than the random effect model, so the estimate of the CACE can be
less efficient; and when study i does not report complete compliance data, it must be
excluded from the two-step approach because θCACEi is no longer directly estimable
by simply using the incomplete data from this individual study, while the function
cace.meta.ic() can use the incomplete information and thus help to improve efficacy
in estimation.
The Gelman and Rubin convergence statistics, time-series standard errors, trace
plots, and auto-correlation plots are provided by the package BayesCACE to examine
whether the MCMC chains are drawn from stationary distributions. However, in prac-
tice, any sample is finite, there is no guaranteed way to prove that the sampler has
converged (Kass et al., 1998; Cowles and Carlin, 1996). Additional techniques may
be required to determine the effective sample size for adequate convergence (Robert
and Casella, 2013). For example, the well-developed R package mcmcse (Flegal et al.,
2017) can be used to assess whether MCMC has been run for enough iterations (suffi-
cient chain lengths). To call the functions in mcmcse, users can specify the argument
mcmc.samples = TRUE in cace.study(), cace.meta.c(), and cace.meta.ic(), so the
MCMC posterior samples of monitored parameters are saved in the output objects.
The current version of BayesCACE only applies to binary outcomes. However, the
Bayesian hierarchical model can be extended to handle ordinal outcomes o ∈ {1, . . . , O}.
By selecting weighting scores {W1,W2, . . . ,WO} to reflect distances between outcomes
categories {1, . . . , O}, θCACEi is defined as E(Y 1ij − Y 0ij |Cij = 1) =
∑
o (Wo × uio) −∑
o (Wo × vio) (Zhou et al., 2019). Equally spaced scores {1, 2, ..., O}, their linear trans-
forms, and midranks are reasonable weight choices (Agresti, 2003). Future work will
add CACE meta-analysis functions for ordinal outcomes, and allow users to choose their
preferred weights {W1,W2, . . . ,WO}. Note that ordinal outcomes lead to more complex
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correlation structures in the parameters related to response rates, so multivariate prior
distributions are necessary to analyze such outcomes. Functions to handle ordinal out-
comes and various random effects options are currently under development and may be




5.1 Summary of major findings
The major contribution of this thesis is that it developed comprehensive Bayesian meth-
ods to estimate CACE in meta-analysis of RCTs with binary or ordinal outcomes, ac-
counting for between-study heterogeneity in noncompliance, or both heterogeneous and
incomplete noncompliance among studies. To implement this method for binary out-
comes, a user-friendly R package BayesCACE is provided, where flexible functions for
analyzing data from a single RCT and from a meta-analysis of multiple RCTs with
either complete or incomplete noncompliance data are developed based on the proposed
Bayesian hierarchical models.
In Chapter 2, the proposed Bayesian hierarchical models that account for the in-
herent heterogeneities between studies and treatment groups in noncompliance were
applied to a real meta-analysis of epidural analgesia trials. The case study suggested
that including appropriate random effects improved the model fit (according to deviance
information criterion) and including different random effects affected the estimates of
parameters. Simulation studies were also performed to evaluate the performance of
our approach and the impact of misspecification of random effects. The simulations
showed that our approach had a good chance of identifying the correct model. When
over-fitting occurred, the credible intervals were noticeably too wide and the coverage
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probabilities were larger than the nominal level, while under-fitting could produce mean-
ingful decrements in coverage probabilities. To the best of our knowledge, this is the
first meta-analysis of RCTs estimating CACE accounting for noncompliance.
The above approach was extended to account for both heterogeneous and incomplete
noncompliance among studies in Chapter 3. The method was applied to the same case
study of epidural analgesia trials. Using the proposed method, all 27 epidural analgesia
trials were included in the CACE meta-analysis. After including the information from
studies with incomplete data, the final model we selected had one more random effect
than when we applied the model to studies with complete data only, indicating that
the added studies may have introduced more heterogeneity and may affect the CACE
estimation. We then conducted simulation studies to evaluate the performance of our
approach under different missingness mechanisms, and the impact of misspecification of
random effects.
Chapter 4 is an application chapter; it introduced the BayesCACE package for con-
ducting CACE analysis with R. Besides meta-analysis, Bayesian hierarchical models
estimating the CACE in individual studies were also reviewed to demonstrate the under-
lying methods of the functions. Real meta-analysis datasets used to illustrate practical
usage of various functions in BayesCACE were epidural_c and epidural_ic, which
corresponded to the case studies analyzed in Chapter 2 and 3. The package also pro-
vided various plot functions for interpretation of model outputs and model diagnosis.
The upcoming publication of the BayesCACE package will allow users to implement
the proposed methods and conduct CACE analysis easily and accurately. We believe
this newly-developed user-friendly statistical tool will be helpful to popularize CACE
meta-analysis methods.
5.2 Future research
Despite the contributions of the Bayesian methods proposed for CACE analysis in meta-
analysis, we plan to pursue several future developments. In particular, inspired by the
discussions in Chapter 2-4, the following topics on causal inference in meta-analysis need
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development.
(1) Extensions to handle more complicated noncompliance and other types of out-
comes. Throughout the thesis, we only considered all-or-none noncompliance (a
dichotomous status) for binary or ordinal outcomes. However, in some trials it is
not practical to only discuss all-or-none noncompliance. For example, if the inter-
vention of a RCT is taking a new medicine versus placebo for 6 weeks, patients’
compliance status can change at different follow-up time points, so it is more rea-
sonable to consider noncompliance as a time dependent variable. Accounting for
such a variable will increase the complexity of defining and estimating causal ef-
fects. Recently, extensions have been developed for estimating causal effects in a
single study, e.g., causal inference on other types of outcomes such as longitudinal
endpoints (Yau and Little, 2001; Pickles and Croudace, 2010) and time-to-event
data (Baker and Kramer, 2005; Lok et al., 2004; Yang et al., 2012). In meta-
analysis, potential future topics can be chosen from extending the above causal
inference research progress from a single study to meta-analysis.
(2) Relaxing certain key assumptions. The CACE framework is valid under five
essential assumptions: SUTVA, random assignment, the exclusion restriction,
E[T 1ij − T 0ij ] 6= 0, and monotonicity. These assumptions are plausible in our
epidural analgesia case studies, as discussed in Section 2.2.1. However, some
assumptions may not be satisfied in other applications. Research on relaxing cer-
tain key assumptions has been developed for a single randomized trial, including
estimating causal effects in the presence of interference (Hudgens and Halloran,
2008; Liu and Hudgens, 2014) and noncompliance measured with error (Imai and
Yamamoto, 2010), etc.. Extensions to meta-analysis accounting for these assump-
tions violations await further development.
(3) Causal inference in network meta-anlaysis. Network meta-analysis has recently
attracted much attention in evidence-based medicine. It expands the scope of
a conventional pairwise meta-analysis to simultaneously compare multiple treat-
ments by synthesizing both direct and indirect information (Lumley, 2002; Zhang
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et al., 2014). It can also be used to select the best treatment(s) and to estimate the
uncertainty in the treatment ranking and thus facilitates better decision making.
Extending the CACE meta-analysis methods to network meta-analysis is also a
promising future research topic that awaits further exploration.
(4) Future work for user-friendly software. As discussed in Section 4.4, the current
version of the BayesCACE package provides extensive options for fitting different
CACE models, but the functions only apply to binary outcomes. Our proposed
Bayesian hierarchical methods can also handle ordinal outcomes, though they
bring more complex correlation structures for the parameters and require multi-
variate prior distributions. We will continue to develop this R package to further
expand on what is currently available. Future work would add functions for ordi-
nal outcomes and various random effects options. In the meantime, a frequentist
alternative method via the generalized linear mixed model (GLMM) can also be
applied to estimate CACE in meta-analysis, and these models are easy to imple-
ment in SAS. In addition to the Bayesian approach available from the proposed
R package, we plan to release user-friendly SAS macros with a tutorial paper so
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A.1 Data display for the case study
Table A1 shows the frequencies of cesarean deliveries, based on the allocated intervention
and the actual received analgesia, for the 10 trials analyzed in Section 3. In the table,
nirto refers to observed count for outcome o in the i
th study group {j : Rij = r, Tij = t},
o ∈ {0, 1}.
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Table A1: Data in 10 randomized controlled trials of epidural analgesia in labor
Study
(Author, Year)
Allocated control Allocated epidural

















Bofill, 1997 37 2 11 1 2 0 42 5
Clark, 1998 72 6 68 16 7 2 134 13
Halpern, 2004 62 5 44 7 0 0 112 12
Head, 2002 51 7 2 0 3 0 43 10
Jain, 2003 72 11 0 0 0 2 36 7
Nafisi, 2006 179 19 0 0 0 0 173 24
Nirkola, 1997 6 0 4 0 0 0 10 0
Ramin, 1995 546 17 95 8 230 0 393 39
Sharma, 1997 336 16 5 0 114 1 231 12
Volmanen, 2008 23 1 3 0 1 0 23 1
A.2 Parameter estimates of the case study
Table A2 presents parameter estimates from the fixed effects model (Model I) and the
final model (Model IVa) in Section 3.3. We used the triple of percentiles, 2.55097.5,
to display a parameter posterior median with its 95% equal tail credible interval, as
suggested by Louis and Zeger (2009). Monte Carlo integration (Ueberhuber, 1997)
was used to estimate the overall probabilities of being a principal stratum, πa, πc,
and πn when δin and δia were both present (Model IVa), and the overall never-taker
response rate, s1 = E(si1) of Model IVa was estimated using the approximation E(si1) ≈
logit−1( αs√
1+C2σ2s
), C = 16
√
3
15π . Estimates for other overall response rates, b1, u1, v1, and
θCACE were directly from the fixed parameters because no random effect on those rates
was included in either Model I or Model IVa. For example, bi1 were assumed to be the
same across studies according to the models so we estimated b1 = E(bi1) = logit
−1(αb).
Based on the final Model IVa, the posterior estimate of θCACE was −0.0030.0220.048, which
covered zero and indicated a nonsignificant complier average causal effect of epidural
analgesia in labor on cesarean section. The random effects of ni and ai had standard
deviations of 1.619 and 1.912, while the random effect of s1 had a standard deviation of
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2.004 on the logit scale. After adding random effects δia, δin and δis, the estimates of the
mean parameters of ni and ai from Model IVa were much different from the estimates
from Model I.
Table A2: Summary of parameter estimates using Bayesian hierarchical models for 10
RCTs of epidural analgesia in labor
Parameter Model I (None) Model IVa (δia, δin, δis)
θCACE −0.0110.0160.044 −0.0030.0220.048
Overall never-taker probability πn 0.1970.2160.236 0.0830.0960.116
Overall always-taker probability πa 0.1360.1530.170 0.1550.1860.223
Overall complier probability πc 0.6040.6310.656 0.6770.7170.752
Overall never-taker response s1 0.0100.0210.039 0.0500.1720.455
Always-taker response b1 0.0870.1230.166 0.0820.1130.148
Treated complier response u1 0.0650.0860.108 0.0720.0910.111
Control complier response v1 0.0530.0690.087 0.0530.0690.086
Mean parameter of ni −1.197−1.070−0.945 −4.154−2.828−1.716
Mean parameter of ai −1.562−1.419−1.280 −3.452−2.168−0.893
Standard deviation of ni – 1.0241.6192.888
Standard deviation of ai – 1.2351.9123.303
Standard deviation of logit(si1) – 1.0612.0044.354
The triple notation of LPU denotes the posterior median P with 95% equal tailed credible
limits (L, U) using Bayesian hierarchical models.
A.3 Sample R code
Sample R JAGS code for Model IVa is shown below. More modeling and simulation
codes are available at our GitHub repository: https://github.com/JinchengZ/CACE meta.
model{
for (i in 1:n) {
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prob[i, 1] <- (pi_n[i]*(1-s1[i]) + pi_c[i]*(1-v1[i]))
prob[i, 2] <- (pi_n[i]*s1[i] + pi_c[i]*v1[i])
prob[i, 3] <- (pi_a[i]*(1-b1[i]))
prob[i, 4] <- (pi_a[i]*b1[i])
prob[i, 5] <- (pi_n[i]*(1-s1[i]))
prob[i, 6] <- (pi_n[i]*s1[i])
prob[i, 7] <- (pi_c[i]*(1-u1[i])+pi_a[i]*(1-b1[i]))
prob[i, 8] <- (pi_c[i]*u1[i]+pi_a[i]*b1[i])
R[i, 1:4] ~ dmulti(prob[i, 1:4], N0[i])
R[i, 5:8] ~ dmulti(prob[i, 5:8], N1[i])
probit(u1[i]) <- alpha_u
probit(v1[i]) <- alpha_v
n[i] <- alpha_n + delta_n[i]
delta_n[i] ~ dnorm(0, tau_n)
a[i] <- alpha_a + delta_a[i]




logit(s1[i]) <- alpha_s1 + delta_s[i]






alpha_n ~ dnorm(0, 0.16)
tau_n ~ dgamma(2, 2)
sigma_n <- 1/sqrt(tau_n)
alpha_a ~ dnorm(0, 0.16)
tau_a ~ dgamma(2, 2)
sigma_a <- 1/sqrt(tau_a)
alpha_s1 ~ dnorm(0, 0.25)
tau_s ~ dgamma(2, 2)
sigma_s <- 1/sqrt(tau_s)
alpha_b1 ~ dnorm(0, 0.25)
alpha_u ~ dnorm(0, 0.25)
alpha_v ~ dnorm(0, 0.25)
}
A.4 Sensitivity analysis on priors in the case study
In a sensitivity analysis of the prior specification, we repeated our analysis of the final
model (Model IVa) using two different sets of priors for the variance parameters of
random effects, which were more diffuse than the ones presented earlier. Specifically,
we considered Gamma(1, 1) and Gamma(0.5, 0.5) as priors for σ−2n , σ
−2
a , and σ
−2
s ,
which correspond to a 95% interval for the variance parameters of (0.27, 39.50) and
(0.2, 1018.3), respectively. The posterior estimate of θCACE was −0.00350.02230.0483 when
using Gamma(1, 1), and −0.00320.02230.0483 under Gamma(0.5, 0.5). Comparing the
result −0.00340.02220.0481 from Model IVa, the posterior estimate of θ
CACE did not change
to the third digit. Therefore, for the priors considered, the results were consistent.
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A.5 Additional simulation results
In addition to the four data generating settings presented in Table 4, we added two
additional settings and displayed the mean, bias, 95% credible interval length, and
coverage probability for θCACE under each candidate model. In both scenarios the data
were generated from a full model as introduced in Section 2.4, with all of the 6 possible
random variables included. In the first setting we used the probit link function for ui1
and vi1, while in the second scenario a logit link was used. Sample sizes, allocation
ratio, and true values were set the same as described in Section 4. The variances of δin,
δia, δis, δib, δiu and δiv were set to 0.5
2, and the true correlation between δin and δia
was 0.5. Besides the 8 candidate models with up to 3 random effects, we also fitted the
generated data with the full model (6 random effects, probit link for ui1 and vi1).
As θCACE is only related with ui1 (the response rate of a treated complier) and
vi1 (the response rate of complier in control), failure to include the random effect for
δiu and δiv reduces the coverage probability for θ
CACE substantially. In the meantime,
including random effect on δiu and δiv tend to give longer 95% credible intervals. In the
second setting we simulated heterogeneous θCACEi using the logit link for ui1 and vi1,
but fitted all candidate models with probit link, in order to check if our proposed model
still performed well. Results showed that the estimated θCACE regarding the bias, 95%
credible interval length, and coverage probability were pretty much the same as those
under the correct link function, which were as expected because the normal and logistic
cumulative distribution functions were very close.
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Table A3: Additional performance of estimates and credible intervals for θCACE for each
model, based on 2000 simulated datasets
True Random Selected Random Effects Model
Effects Model None δin δiu δiv δin, δiu δin, δiv δiu, δiv δin, δiu, δiv All
All
probit
Mean -0.347 -0.350 -0.338 -0.338 -0.341 -0.337 -0.329 -0.328 -0.330
Bias -0.002 -0.005 0.007 0.007 0.004 0.008 0.016 0.017 0.015
95% CIL 0.102 0.102 0.212 0.214 0.212 0.215 0.284 0.285 0.278
95% CICp 0.647 0.606 0.954 0.961 0.933 0.958 0.989 0.989 0.988
All
logit
Mean -0.233 -0.234 -0.226 -0.227 -0.227 -0.219 -0.220 -0.219 -0.219
Bias 0.002 0.002 0.009 0.009 0.008 0.016 0.015 0.016 0.016
95% CIL 0.103 0.102 0.198 0.201 0.197 0.264 0.263 0.264 0.260
95% CICp 0.764 0.737 0.982 0.983 0.976 0.997 0.997 0.997 0.997
The bold-face cells represent the correctly chosen model.
95% CIL: 95% equal-tail credible interval length.
95% CICp: 95% credible interval coverage probability.
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